# SUMMARY

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Editorial</td>
<td>3</td>
</tr>
<tr>
<td>Organizing &amp; Scientific Committees</td>
<td>4</td>
</tr>
<tr>
<td>Lifetime Achievement Award</td>
<td>5</td>
</tr>
<tr>
<td>Keynotes</td>
<td>6</td>
</tr>
<tr>
<td>Program at a glance</td>
<td>9</td>
</tr>
<tr>
<td>Program</td>
<td></td>
</tr>
<tr>
<td>Tuesday, November 29</td>
<td>10</td>
</tr>
<tr>
<td>Wednesday, November 30</td>
<td>11</td>
</tr>
<tr>
<td>Thursday, December 1</td>
<td>15</td>
</tr>
<tr>
<td>Friday, December 2</td>
<td>19</td>
</tr>
<tr>
<td>Poster presentations</td>
<td>24</td>
</tr>
<tr>
<td>Practical details</td>
<td>55</td>
</tr>
<tr>
<td>CTAD Partners</td>
<td>56</td>
</tr>
</tbody>
</table>
Dear colleagues,

The field of Alzheimer’s disease diagnostics and therapeutics has become one of the most exciting areas in all of medical research. The Clinical Trials on Alzheimer’s Disease (CTAD) meeting, being held this November 29-December 2, 2022, promises to continue the excitement!

Why is our field so exciting? Rapid progress in our field has resulted from huge investments by governments into basic science research, followed by more recent huge investments by the private sector into diagnostic, biotech, and pharmaceutical companies. It has only been 15 years since molecular imaging with amyloid PET scans first demonstrated the ability to detect Alzheimer’s disease pathology in living people. Now, amyloid PET is widely available, tau PET is being employed by many clinical trials, and very recently blood tests for Alzheimer’s disease have shown great promise for screening, and even for diagnosis.

But, without question there is growing evidence that monoclonal antibodies, which remove amyloid plaque, appear to slow cognitive decline. Unfortunately, these treatments are also associated with ARIA, including brain swelling and bleeding in the brain. There is considerable controversy concerning the significance and impact of these findings, including whether or not governments and medical insurance will provide financial coverage for such treatments.

These issues will be at the center of the CTAD meeting being held in San Francisco. Experts from academics and industry will be attending, presenting their data and discussing the pros and cons of various controversial topics. In addition to the formal program there will be extensive networking and discussions around the poster sessions, coffee breaks, formal receptions, and in the hallways.

San Francisco is an especially beautiful city, surrounded by the Pacific Ocean and the San Francisco Bay. Golden Gate Park, and the Presidio are huge parks filled with trees, flowers and historical sites. We have three internationally famous universities, the world’s largest biotech hub just south of the city, and Silicon Valley further south. Don’t forget to include some vacation time and consider visiting the Muir Woods, the Napa Valley, and Carmel/Big Sur to the south.

I’m looking forward to seeing old friends, and making new ones at the CTAD meeting in beautiful San Francisco.
President of the CTAD22 Scientific Committee
Michael W. WEINER, MD
University of California at San Francisco (UCSF)

Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Miami, USA); Michael C DONOHUE (San Diego, USA); Rachelle DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FILLIT (New York, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T. MIDDLETON (London, UK); José Luis MOLINUEVO (Valby, Denmark); Ronald PETERSEN (Minnesota, USA); Michael S. RAFII (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas, USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Heife, China); Jiong SHI (Las Vegas, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New Haven, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Michael W. WEINER* (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

* Organizing Committee Member
This year the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research is awarded to Reisa Sperling MD, and Keith Johnson, MD, in recognition for their outstanding contributions to the advancement of AD clinical trials research.

Reisa SPERLING MD
Professor of Neurology at Harvard Medical School and Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital, Boston, MA (USA)

Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer’s disease (AD) at the pre-symptomatic or “preclinical” stage of AD. Dr. Sperling is a Professor in Neurology at Harvard Medical School, and Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital and Massachusetts General Hospital. Dr. Sperling is the co-Principal Investigator of the Harvard Aging Brain Study, and the NIH funded Alzheimer’s Clinical Trial Consortium (ACTC). She co-leads the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) Study, and recently launched two new prevention trials in the AHEAD 3-45 Study with the ACTC.

Keith JOHNSON MD
Professor of Radiology and Neurology at Harvard Medical School and Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital, Boston, MA (USA)

Dr. Johnson is a Professor of Radiology and Neurology at the Harvard Medical School. He is also an Associate Radiologist and the Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital (MGH). He also serves as an associate physician and staff neurologist in the Memory Disorders Unit at the Brigham and Women’s Hospital as well as a Clinical Associate in Neurology at the MGH. He is co-director of the Neuroimaging Program of the Massachusetts Alzheimer’s Disease Research Center and its Dominantly Inherited Alzheimer Network (DIAN) research initiatives. He oversees the Clinical Brain Positron Emission Tomography (PET) Service at the MGH and also practices as a neurologist that specializes in neurodegenerative disorders. Dr. Johnson also maintains an Internet teaching atlas of neuroimaging known as the Whole Brain Atlas. His major research interests include the early diagnosis and treatment monitoring of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and dementia with Lewy bodies.
Keynotes

“The Current and Future State of AD plasma biomarkers”

Kaj Blennow, MD, PhD

Academic Chair in Clinical Neurochemistry, University of Gothenburg, Head of the Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Gothenburg, Sweden

Kaj Blennow is Professor and Academic Chair in Clinical Neurochemistry at University of Gothenburg, and Head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital, Gothenburg, Sweden. His main research interest is CSF and blood biomarkers for Alzheimer’s disease (AD) and other brain disorders, and the application of these to increase the understanding of AD pathophysiology, as well as for screening, diagnostics and in therapy monitoring in clinical trials. Dr. Blennow has published more than 1700 original research papers and review articles in peer-reviewed journals, with more than 110,000 citations, and he has an H-index of 151. He is President of the Society for CSF analysis and Clinical Neurochemistry and head of the Alzheimer’s Association QC program for CSF and blood biomarkers.

“Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities”

Suzanne Craft, PhD

Professor in Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

Dr. Suzanne Craft received her Ph.D. from the University of Texas at Austin, and then completed fellowships at Boston University and Harvard Medical School. She has been a faculty member at Washington University in St. Louis and at the University of Washington. In 2012, she joined the faculty at Wake Forest School of Medicine, where she is Professor of Medicine, and Founding Director of the National Institute on Aging-funded Wake Forest Alzheimer’s Disease Research Center. Dr. Craft has served as a member of the Alzheimer’s Association Medical and Scientific Advisory Group, the NIA Board of Scientific Counselors, and the Executive Committee of the Alzheimer’s Clinical Trial Consortium. Dr. Craft’s research program investigates the role of metabolic disorders in the development of Alzheimer’s disease, through translational studies and innovative clinical trials of pharmacologic and dietary intervention to treat or prevent Alzheimer’s disease. She led a ground-breaking multi-site trial of intranasal insulin for the treatment of Alzheimer’s disease that was funded by the National Alzheimer’s Project Act. She has received a prestigious Zenith Award from the Alzheimer’s Association and a National Institute of Health MERIT award for research excellence. Her work has been featured in HBO’s Emmy-award winning series “The Alzheimer’s Project: Momentum in Science”, in the New York Times and Time magazine, as well as on BBC Newshour, and PBS Newshour.
"Precision Prevention of Dementia and Alzheimer’s Disease: Advancing Multidomain Interventions"

Mia Kivipelto, MD, PhD
Professor in Clinical Geriatrics at Karolinska Institutet, Center for Alzheimer Research, and Director of Research and Development at Karolinska University Hospital, Stockholm (Sweden)

Mia Kivipelto is Professor in Clinical Geriatrics at Karolinska Institutet (KI), Center for Alzheimer Research and senior geriatrician and Director of Research & Development at Theme Aging and Inflammation and Medical Unit Aging at Karolinska University Hospital, Stockholm, Sweden. Part of her Nordic Brain Network multidisciplinary research team (around 100 researchers and clinical staff) is located at University of Eastern Finland and Imperial College London, UK, where she has part time position as Professor. Her frontline research findings have been published in leading journals (340+ publications, H-index 78) and she has received numerous prestigious awards. Dr. Kivipelto’s translational research focuses on the prevention, early diagnosis and treatment of cognitive impairment, dementia and Alzheimer’s disease (AD). Through epidemiological studies, Prof. Kivipelto has identified various lifestyle and vascular risk factors for dementia and interactions with genetic factors and clarified underlying mechanisms. She is the PI of the landmark FINGER trial and founder and scientific leader of World-Wide FINGERS network. Professor Kivipelto is often invited to leading global dementia conferences and task forces.

“Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease”

Roger Nitsch, MD
CEO and President Neurimmune, Schlieren (Switzerland)

Roger Nitsch serves as CEO and President of Neurimmune, which he founded in 2006 with two business partners. A neuroscientist with a background in medicine, Roger is recognized as an opinion leader in neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research. He is a Potamkin Prize winner and Member of the German Academy of Sciences and served as a founding director of the Institute for Regenerative Medicine (IREM), University of Zurich. Roger holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.
ONSITE PROGRAM in San Francisco Available via livestream on the CTAD22 digital platform
Program at a glance

**Tuesday, NOVEMBER 29**

4.00 p.m  Opening Ceremony and CTAD Lifetime Achievement Award

4.30 p.m  KEYNOTE 1: Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities

4.50 p.m  Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab in Early Alzheimer’s Disease

6.30 - 7.30 p.m  CTAD Welcome Reception with the support of the Alzheimer’s Association

**Wednesday, NOVEMBER 30**

8.00 a.m  Welcome coffee - Poster Walking Tour

9.00 a.m  KEYNOTE 2: Precision Prevention of Dementia and Alzheimer’s Disease: Advancing Multidomain Interventions

9.20 a.m  SYMPOSIUM 1: CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials

10.00 a.m  Coffee break and poster session

10.30 a.m  LATE BREAKING ORAL COMMUNICATIONS

11.00 a.m  ORAL COMMUNICATIONS

11.20 a.m  Coffee break and poster session

11.40 a.m  SYMPOSIUM 2: Decentralization Approaches for Clinical Trials on Alzheimer’s Disease

2.00 p.m  ORAL COMMUNICATIONS’ FOCUS SESSION: New Insights for Amyloid and Tau PET Imaging

3.00 p.m  LATE BREAKING COMMUNICATIONS

3.15 p.m  Coffee break and poster session

4.15 p.m  Topline Results of Phase III GRADUATE I & II Pivotal Trials with Subcutaneous Gantenerumab

**Thursday, DECEMBER 1**

8.00 a.m  Welcome coffee - Poster Walking Tour

9.00 a.m  KEYNOTE 3: The Current and Future State of AD plasma biomarkers

9.20 a.m  CTAD open discussion: Anti Amyloid Phase 3 results

9.50 a.m  ORAL COMMUNICATIONS’ FOCUS SESSION: Beyond Amyloid and Tau: Emerging solutions

10.55 a.m  Coffee break and poster session

11.20 a.m  Tackling Agitation in Alzheimer’s Dementia: Brexpiprazole phase III trial results

12.00 p.m  LATE BREAKING ORAL COMMUNICATIONS

12.30 p.m  Lunch on your own and poster session

1.30 p.m  ORAL COMMUNICATIONS

2.30 p.m  ROUNDTABLE 1: Investments in Innovation: Advancing the Path Forward to New Alzheimer’s Treatments

3.00 p.m  ORAL COMMUNICATIONS

4.00 p.m  Coffee break and poster session

4.30 p.m  LATE BREAKING ORAL COMMUNICATIONS

**Friday, DECEMBER 2**

8.00 a.m  Welcome coffee - Poster Walking Tour

9.00 a.m  KEYNOTE 4: Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease

9.20 a.m  LATE BREAKING ORAL COMMUNICATIONS

10.20 a.m  Coffee break and poster session

10.45 a.m  ROUNDTABLE 2: The Alzheimer’s disease Patient Pathway from a sex and gender lens

11.15 a.m  ORAL COMMUNICATIONS’ FOCUS SESSION: Interim or preliminary data and study design

12.05 p.m  Lunch on your own and poster session

1.05 p.m  ORAL COMMUNICATIONS

1.35 p.m  ORAL COMMUNICATIONS’ FOCUS SESSION: Clinical Trials Phase 1 Results

2.05 p.m  ORAL COMMUNICATIONS

3.05 p.m  Coffee break and poster session

3.35 p.m  LATE BREAKING ORAL COMMUNICATIONS

3.50 p.m  ORAL COMMUNICATIONS
Opening Ceremony
Mike Weiner, UCSF, San Francisco, CA (USA), Jacques Touchon, Montpellier University, Montpellier (France), Paul Aisen, Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA (USA), Bruno Vellas, Gerontopole, Toulouse University, Toulouse (France)

CTAD Lifetime Achievement Award Alzheimer’s Disease Therapeutic Research
Presented to Reisa Sperling and Keith Johnson, in recognition for their outstanding contributions to the advancement of AD clinical trials research
Introduction by Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (USA).

KEYNOTE 1
Targeting Immuno-Metabolic Pathways in Alzheimer’s Disease: Novel Mechanisms and Therapeutic Opportunities
Introduction by Jacques Touchon, Montpellier University, Montpellier (France)
Suzanne Craft, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab in Early Alzheimer’s Disease
Chairman: Takeshi Iwatsubo, University of Tokyo - Tokyo (Japan)
Presentation 1: Clarity AD: Clinical Trial Background and Study Design Overview
Michael Irizarry, Eisai Inc. - Nutley, NJ (United States)
Presentation 2: Lecanemab for the Treatment of Early Alzheimer’s Disease: Topline Efficacy Results from Clarity AD
Christopher van Dyck, Yale School of Medicine - New Haven, CT (United States)
Presentation 3: Safety Profile of Lecanemab in Early Alzheimer’s Disease
Marwan Sabbagh, Barrow Neurological Institute - Phoenix, AZ (United States)
Presentation 4: Imaging, Plasma, and CSF Biomarkers Assessments from Clarity AD
Randall J. Bateman, Washington University - St. Louis, MO (United States)
Presentation 5: Context of Clarity AD Results
Sharon Cohen, Toronto Memory Program - Toronto, Ontario (Canada)
Panel Discussion and Q&A

End of the Conference Day

6.05 p.m

6.30 - 7.30 p.m CTAD Welcome Reception with the support of the Alzheimer’s Association
Continental Ballroom - Tower 3
08.00 a.m Welcome coffee - NEW this year at CTAD > Poster Walking Tour

9.00 a.m KEYNOTE 2
Precision Prevention of Dementia and Alzheimer’s Disease: Advancing Multidomain Interventions
Introduction: Bruno Vellas, Toulouse University Hospital, Toulouse (France)
Miia Kivipelto, Karolinska Institutet, Center for Alzheimer Research, Karolinska University Hospital, Stockholm (Sweden)

9.20 a.m SYMPOSIUM 1
CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials
Chair: Kaj Blennow, University of Gothenburg, Gothenburg (Sweden)

- Presentation 1: Relationship between blood plasma and CSF measures of Aβ 42/40, tau, and NFL species for tracking drug effects in clinical trials of Alzheimer’s disease
  Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (USA)

- Presentation 2: Consideration and use of AT(N) blood-based biomarkers for community screening
  Michelle M. Mielke, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

- Presentation 3: Implementation of plasma biomarkers into clinical practice and trials
  Oskar Hansson, Lund University, Lund (Sweden)

10.00 a.m Coffee break and poster session

10.30 a.m LATE BREAKING ORAL COMMUNICATIONS
Chairs: Reisa Sperling, Brigham and Women’s Hospital - Boston, MA (United States), Robert Rissman, UC San Diego and University of Southern California - San Diego, CA (United States)

- LB1 - Tau PET associated with plasma p-tau217 and cognitive testing in preclinical AD: Screening data from the AHEAD Study A3 and A45 Trials
  Keith Johnson 1, Aaron Schultz 1, Robert Rissman 2, Oliver Langford 2, Emma Thibault 1, Matthew Meyer 2, Kristopher Kirmess 3, Michael Irizarry 4, Jin Zhou 2, Michael Donohue 2, Rema Raman 2, Paul Aisen 2, Reisa Sperling 6, Ahead 3-45 Study Team 6
  1Massachusetts General Hospital - Boston (United States), 2University of Southern California - San Diego (United States), 3C2N Diagnostics - St. Louis (United States), 4Eisai - Nutley (United States), 5Brigham and Women’s Hospital - Boston (United States), 6ACTC - Many Sites (United States)

- LB2 - Plasma levels of Abeta42/40 and p-tau217 ratios increase accuracy of amyloid PET prediction in preclinical AD
  Robert Rissman 1, 2, Oliver Langford 2, Michael Donohue 2, Rema Raman 2, Sara Abdel-Latif 2, Matthew Meyer 2, Kristopher Kirmess 2, Joel Braunstein 1, Michael Irizarry 4, Keith Johnson 1, Paul Aisen 2, Reisa Sperling 6, Team Ahead 3-45 Study 6
  1UC San Diego - La Jolla, Ca (United States), 2University of Southern California - San Diego, Ca (United States), 3C2N Diagnostics - St. Louis (United States), 4Eisai - Indianapolis, In (United States), 5Massachusetts General Hospital, Harvard University - Boston, Ma (United States), 6Brigham and Woman’s Hospital, Harvey - Boston, Ma (United States), 7ACTC - San Diego, Ca (United States)

11.00 a.m ORAL COMMUNICATIONS
Chairs: Michael Irizarry, Eisai Inc. - Nutley, NJ (United States) and Michael Weiner, UCSF, San Francisco, CA (United States)

- OCI - ACI-35.030 and JACI-35.064, two novel anti-phospho-Tau vaccines for the treatment of Alzheimer’s Disease: Interim Phase Ib/2a data on safety, tolerability and immunogenicity
  Johannes Streffer 1, Julien Mermoud 1, Olivier Sol 1, Marija Vukicevic 1, Emma Fiorini 1, Eva Gollwitzer 1, Valérie Hliva 1, David Hickman 1, Julian Gray 1, Piergiorgio Donati 1, Maria Pilar Lopez Deber 1, Julien Rongère 1, Andrea Pleifer 1, Marie Kosco-Vilbois 1, Philip Scheltens 3
  1AC Immune SA - Lausanne (Switzerland), 2University of Antwerp - Antwerp (Belgium), 3VUMC - Amsterdam (The Netherlands)
Wednesday, NOVEMBER 30

11.15 a.m
OC2 - Results of a Phase 2/3 Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study to Evaluate the Efficacy and Safety of 12 Week Treatment with the Phosphodiesterase 9 (PDE9) inhibitor Irsenontrine (E2027) in Subjects With Dementia With Lewy Bodies
Michael Irizarry 1, Robert Lai 2, Steven Hersch 1, Kate Pinner 2, Shobha Dhadda 1, Lynn Kramer 1
1Eisai Inc. - Nutley (United States), 2Eisai Ltd. - Hattfield (United Kingdom)

11.30 a.m
OC3 - HMTM Topline Results of Phase 3 LUCIDITY – The First Tau Aggregation Inhibitor
Bjoern Schelter 1,2
1TauRx Therapeutics Ltd - Aberdeen (United Kingdom), 2University of Aberdeen - Aberdeen (United Kingdom)

11.45 a.m
OC4 - Janssen Simoa Plasma p217+tau assay as a precision prescreening tool in Autonomy Ph2 anti-tau monoclonal Ab trial in early Alzheimer’s Disease
Gallen Triana-Baltzer 1, Ziad Saad 1, Setareh Moughadam 1, Randy Slemmon 1, Mary Quiceno 1, David Henley 1, Hartmuth Kolb 1
1Janssen Research & Development - San Diego (United States)

12.00 p.m
OC5 - Long term and economic outcomes for mirtazapine and carbamazepine versus placebo: new data from the SYMBAD RCT
Sube Banerjee On Behalf Of The Symbad Group 1
1University Of Plymouth - Plymouth (United Kingdom)

12.15 p.m Lunch on your own and poster session Yosemite/Imperial Ballroom & Registration area - Tower 2

1.20 p.m
SYMPOSIUM 2
Decentralization Approaches for Clinical Trials on Alzheimer’s Disease
Chair: Holly Massett, National Institute on Aging – Bethesda, MD (United States)

Presentation 1: Remote assessments in a follow-on study from TRAILBLAZER-ALZ
Jessica Langbaum, Banner Alzheimer’s Institute - Phoenix, AZ (United States)

Presentation 2: Effects of supervision on cognitive and functional assessment outcomes
Paul Maruff, CogState - Melbourne (Australia)

Presentation 3: Decentralization approaches in TRAILBLAZER-ALZ 3
Roy Yaari, Eli Lilly and Company – Indianapolis, IN (United States)

Presentation 4: Investigator experience in a decentralized clinical trial on Alzheimer’s Disease
Ralph Lee, Irvine Clinical Research - Irvine, CA (United States)

2.00 p.m
ORAL COMMUNICATIONS’ FOCUS SESSION: New Insights for Amyloid and Tau PET Imaging
Chairs: Jessica Langbaum, Banner Alzheimer’s Institute - Phoenix, AZ (United States), Oskar Hansson, Lund University, Lund (Sweden)

2.00 p.m
OC6 - Combination of regional flortaucipir quantification and event-based modeling in clinical trial analyses
Ixavier Higgins 1, Amanda Morris 1, John Sims 1, Mark Mintun 1, Sergey Shcherbinin 1
1Eli Lilly and Company - Indianapolis (United States)

2.10 p.m
OC7 - Longitudinal Tau PET increase is highest in brain regions with strongest functional connectivity to regions with most NFT at Baseline: An independent validation
Ziad S. Saad 1, Ritobrato Datta 1, Christopher Rowe 2, Hartmuth C. Kolb 1
1Janssen R&D, Johnson & Johnson - San Diego (United States), 2Austin Health and University of Melbourne - Melbourne (Australia)

2.20 p.m
OC8 - Individualised tau-PET measures might be superior to group level measures when determining change in tau deposition over time in Alzheimer’s disease
Antoine Leuzy 1, Alexa Pichet-Binette 1, Jacob W. Vogel 1, Gregory Klein 1, Edilio Borroni 1, Matteo Tonietto 1, Olof Strandberg 1, Niklas Mattsson-Carlsgren 1, Sebastian Palmqvist 1, Erik Stomrud 1, Rik Ossenkoppele 1, Ruben Smith 1, Oskar Hansson 1
1Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund (Sweden), 2Penn/CHOP Lifespan Brain Institute, University of Pennsylvania, Philadelphia (United States), 3F. Hoffmann-La Roche Ltd, Basel (Switzerland)
OC9 - Prevalence and longitudinal clinical outcomes of visually 18F-flortaucipir PET-positive individuals across the Alzheimer's disease spectrum
Alexis Moscoso 1, Fiona Heeman 2, Vallee Camacho 2, Martijn Van Essen 3, Michel J Grothe 4, Li Lin 5, Ismini Mainta 6, Federica Ribaldi 7, Michael D Devous 8, Michael J Pontecorvo 9, Giovanni B Frisoni 7, Valentina Garibotto 7, Michael Schöll 1
1Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden), 2Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain - Barcelona (Spain), 3Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden. - Gothenburg (Sweden), 4Movement Disorders Group, Institute of Biomedicine of Seville-IIS, Seville, Spain. - Seville (Spain), 5Department of radiology, the third affiliated hospital of sun yat-sen university. - Guangzhou (China), 6Division of Nuclear Medicine, Geneva University Hospitals, Geneva, Switzerland - Genève (Switzerland), 7Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland - Genève (Switzerland), 8Avid Radiopharmaceuticals, Philadelphia, PA, USA - Philadelphia (United States)

2.40 p.m
OC10 - Concordance of Visual and Quantitative Analysis for Amyloid PET Imaging With Three 18F Tracers in the CHARIOT-PRO Substudy
Gerald Novak 1, Ziad Saad 2, David Scott 3, Chi Udeh-Momoh 4, Luc Bracoud 5, Craig Ritchie 6, Lefkos Middleton 7
1Janssen R&D - Titusville, Nj (United States), 2Janssen R&D - La Jolla, Ca (United States), 3Clario (formerly Bioclinica) - San Mateo, Ca (United States), 4Imperial College - London (United Kingdom), 5Clario (formerly Bioclinica) - Lyon (France), 6University of edinburgh - Edinburgh (United Kingdom), 7Imperial College - Edinburgh (United Kingdom)

2.50 p.m
OC11 - AmyloidIQ quantification strongly agrees with both histopathology and visual reads across multiple amyloid tracers
Alex Whittington 1, Santiago Bullich 2, Lily Porat 1, Roger Gunn 1
1Invicro - London (United Kingdom), 2Life Molecular Imaging - Berlin (Germany)

3.00 p.m
LATE BREAKING ORAL COMMUNICATIONS
Chairs: Kristine Yaffe, UCSF, San Francisco, CA (United States), Stephen Salloway, Alpert Medical School of Brown University, Providence, RI (United States)

3.00 p.m
LB3 - TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease
Stephen Salloway 1, Elly Lee 1, Michelle Papka 3, Andrew Pain 4, Ena Oru 4, Margaret B. Ferguson 4, Hong Wang 4, Michael Case 4, Ming Lu 5, Emily C. Collins 5, Dawn Brooks 5, John Sims 5
1Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, And Providence, RI, USA, Butler Hospital - Providence (United States), 2Irvine Clinical Research - Irvine (United States), 3The Cognitive and Research Center of New Jersey LLC - Springfield (United States), 4Eli Lilly and Company - Indianapolis - Indianapolis (United States)

3.15 p.m
LB4 - CSF MTBR-tau243 is a non-amyloid specific biomarker of neurofibrillary tangles of Alzheimer’s disease
Kanta Horie 1, 2, Gemma Salvadó 3, Nicolas Barthélémy 1, Yan Li 1, Benjamin Saef 1, Charlie Chen 1, Hong Jiang 1, Brian Gordon 1, Tammie Benzinger 1, David Holtzman 1, Suzanne Schindler 1, Oskar Hansson 1, 2, Randall Bateman 1
1Washington University School of Medicine - St. Louis (United States), 2Elisai Inc. - Nutley (United States), 3Lund University - Lund (Sweden), 4Skåne University Hospital - Malmö (Sweden)

3.30 p.m
LB5 - Top-line Results from the 2-Year Systematic Multi-domain Alzheimer’s Risk Reduction Trial (SMARRT)
Kristine Yaffe 1, Eric Vittinghoff 1, Sascha Dublin 2, Carrie Peltz 1, Lynn Fleckenstein 1, Dori Rosenberg 1, Deborah Barnes 1, Benjamin Balderson 1, Eric Larson 1
1University of California, San Francisco - San Francisco, Ca (United States), 2Kaiser Permanente Washington Health Research Institute - Seattle, Wa (United States), 1University of Washington - Seattle, Wa (United States)

3.45 p.m
Coffee break and poster session Yosemite/Imperial Ballroom & Registration area - Tower 2
4.15 p.m

Topline Results of Phase III GRADUATE I & II Pivotal Trials with Subcutaneous Gantenerumab
Chair: Jeffrey F Cummings, Chambers-Grundy Center for Transformative Neuroscience, University of Nevada Las Vegas (UNLV) - Las Vegas, NV (United States)
Presenter: Randall J Bateman, Washington University School of Medicine - Saint Louis, MO, (United States)
Panelists: Rachelle S Doody 1,2, Stephen P Salloway 3 Sandra E Black 4,5
1F. Hoffmann-La Roche Ltd – Basel (Switzerland), 2Genentech, Inc – South San Francisco, CA, (United States), 3Butler Hospital and Warren Alpert Medical School of Brown University - Providence, RI, (United States), 4Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre - Toronto, Ontario (Canada), 5 LC Campbell Cognitive Neurology Research Unit, Dr Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto - Toronto, Ontario (Canada)

5.15 p.m

End of the Conference Day
Thursday, DECEMBER 1

08:00 a.m Welcome coffee

9.00 a.m
**KEYNOTE 3**
The Current and Future State of AD plasma biomarkers
Introduction: Michael Weiner, UCSF - San Francisco, CA (United States)
Kaj Blennow, University of Gothenburg, and Sahlgrenska University Hospital - Gothenburg (Sweden)

9.20 a.m CTAD open discussion: Anti Amyloid Phase 3 results
Maria Carrillo 1, David Knopman 2, Lefkos Middleton 3, Ron Petersen 2
1 Alzheimer’s Association - Chicago, IL (United States), 2 Mayo Clinic - Rochester, MN (United States), 3 Imperial College - London (United Kingdom)

9.50 a.m
**ORAL COMMUNICATIONS’ FOCUS SESSION: Beyond Amyloid and Tau: Emerging solutions**
Chair: Howard Fillit, Alzheimer’s Drug Discovery Foundation, New York, NY (USA)

9.55 a.m
**OC12 - Topline Results of EXERT: Can Exercise Protect Against Cognitive Decline in MCI?**
Carl Cotman 1, Howard Feldman 2, Andrea Lacroix 3, Aladdin Shadyab 4, Diane Jacobs 5, David Salmon 2, Ron Thomas 2, Shelia Jin 2, Judy Pa 2, Jeffrey Katula 3, Robert Rissman 4, James Brewer 5, Youngkyoo Jung 6, Jing Zhang 6, Laura Baker 6
1 UCI (United States), 2 UCSD (United States), 3 Wake Forest University (United States), 4 UC Davis (United States), 5 Wake Forest University School of Medicine (United States)

10.10 a.m
**OC13 - Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD) – Pilot Study Results on Central Nervous System Penetration and Alzheimer’s Disease Biomarkers**
Mitzi Gonzalez 1, Valentina Garbarino 1, Tiffany Kautz 1, Ronald Petersen 2, Tamara Tchkonia 3, James Kirkland 3, Suzanne Craft 3, Sudha Seshadri 1, Nicolas Musi 1, Mirandra Orr 2
1 UT Health San Antonio - San Antonio (United States), 2 Mayo Clinic - Rochester (United States), 3 Wake Forest School Of Medicine - Winston-Salem (United States)

10.25 a.m
**OC14 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients**
Ronald Van Der Geest 1, Anastasia Lili 1, Oscar Van Loosbroek 1, Andreia Almeida 1, Marlies Oosthoek 2, Charlotte Teenissen 2, Sietske Sikkes 3, Everard Vlijverberg 2
1 Tweekay TW001AD BV - Tilburg (Netherlands), 2 Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), 3 Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands)

10.40 a.m
**OC15 - Protein Biomarkers in Autosomal Dominant Alzheimer’s Disease Cerebrospinal Fluid Identify Early Changes in Brain Glucose Metabolism and the Matrisome**
Shijia Bian 1, E. Kathleen Carter 1, Rafi Haque 1, Caroline Watson 1, Brian Gordon 2, Lingyang Ping 1, Duc Duong 1, Michael Epstein 1, James Lahn 1, Blaine Roberts 1, Anne Fagan 2, Nicholas Seyfried 1, Allan Levey 1, Erik Johnson 1
1 Emory University - Atlanta (United States), 2 Washington University - St. Louis (United States)

10.55 a.m Coffee break and poster session

11.20 a.m
**Tackling Agitation in Alzheimer’s Dementia: Brexipiprazole phase III trial results**
George Grossberg 1, Daniel Lee 2, Mary Slomkowski 2, Nanco Hefting 3, Dalei Chen 2, Klaus Larsen 3, Eva Kohegyi 2, Mary Hobart 2, Jeffrey Cummings 4
1 Department of Psychiatry and Behavioral Neuroscience at Saint Louis University School of Medicine - St. Louis, Missouri (United States), 2 Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), 3 H. Lundbeck A/S - Valby, Copenhagen (Denmark), 4 Chambers-Grundy Center for Transformative Neuroscience at School of Integrated Health Sciences University of Nevada Las Vegas (UNLV) - Las Vegas, Nevada (United States)

Panel discussion: Mary Sano 1, Bruno Vellas 2, Clive Ballard 1, Alireza Atri 4
1 Mount Sinai School of Medicine - New York, NY (United States), 2 Toulouse University Hospital - Toulouse (France), 3 University of Exeter Medical School - Exeter (United Kingdom), 4 Banner Sun Health Research Institute - Phoenix, AZ (United States)
Thursday, DECEMBER 1

12.00 p.m LATE BREAKING ORAL COMMUNICATIONS
Chairs: Maria Carrillo, Alzheimer's Association - Chicago, IL (United States), Pierre-Jean Ousset, Toulouse University Hospital - Toulouse (France)

12.00 p.m LBG - Two-year prognostic utility of plasma p217+tau in the Alzheimer continuum
Azadeh Feizpour 1,2, Vincent Doré 3,4, James D. Doecke 1, Ziad Saad 5, Natasha Krishnadas 1,2, Christopher Fowler 1, Larry Ward 1, Ralph N. Martins 6,7, Colin L. Masters 1, Victor L. Villemagne 2,8, Jurgen Fripp 4, Hartmuth C. Kolb 3, Christopher C. Rowe 2,9.
1The Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia - Melbourne (Australia), 2Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia - Melbourne (Australia), 3The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia - Melbourne (Australia), 4The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia - Brisbane (Australia), 5Neuroscience Biomarkers, Janssen Research and Development, La Jolla, CA, USA - San Diego (United States), 6Edith Cowan University - Perth (Australia), 7McCusker Alzheimer's Research Foundation, Nedlands, - Perth (Australia), 8Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA - Pittsburgh (United States), 9Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia - Melbourne (Australia)

12.15 p.m LB7 - ALZ-NET: Using Real World Evidence to Define the Future of Alzheimer’s Treatment and Care
Maria Carrillo 1, Gil Rabinovici 2, Michael Rafii 3
1Alzheimer’s Association - Chicago (United States), 2Memory and Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco - San Francisco (United States), 3Alzheimer’s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California - San Diego (United States)

12.30 p.m Lunch on your own and poster session Yosemite/Imperial Ballroom & Registration area - Tower 2

1.30 p.m ORAL COMMUNICATIONS
Chairs: Philip Scheltens, LSP Dementia Fund at EQT Life, Alzheimer Centre Amsterdam, Amsterdam (The Netherlands), Andrew Stern, Brigham And Women’s Hospital, Harvard Medical School - Boston, MA (United States)

1.30 p.m OC16 - Leveraging novel technologies to design and implement more patient focused clinical trials
Dave Miller 1
1Unlearn.AI - Berkeley (United States)

1.45 p.m OC17 - Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?
Rik Ossenkoppele 1, Alexa Pichet Binette 1, Colin Groot 1, Reisa Sperling 2, Colin Masters 3, Wiesje Van Der Flier 4, William Jagust 5, Petersen Ronald 6, Clifford Jack 6, Oskar Hansson 1
1Lund University - Lund (Sweden), 2MGH - Boston (United States), 3The Florey Institute Of Neuroscience And Mental Health Melbourne Victoria Australia - Parkville (Australia), 4Amsterdam University Medical Center - Amsterdam (Netherlands), 5UC Berkeley - Berkeley (United States), 6Mayo Clinic - Rochester (United States)

2.00 p.m OC18 - Plasma NT1-tau correlates with age and cognitive decline in two large Down syndrome cohorts
Andrew M. Stern 1, Kathryn L. Van Pelt 2, Lei Liu 1, Amirah K. Anderson 1, Beth Ostaszewski 1, Dennis J. Selkoe 1, Frederick Schmitt 1, Elizabeth Head 3
1Ann Romney Center For Neurologic Diseases, Brigham And Women’s Hospital, Harvard Medical School - Boston, MA (United States), 2Sanders-Brown Center For Aging, Department Of Neurology, University Of Kentucky - Lexington, KY (United States), 3Department Of Pathology And Laboratory Medicine, University Of California, Irvine - Irvine, CA (United States)

2.15 p.m OC19 - Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle burden
Gemma Salvadó 1, Rik Ossenkoppele 1,2, Nicholas J Ashton 3,4,5, Thomas G Beach 6, Geidy E Serrano 4, Gwenlwynd Kollmorgen 1, Henrik Zetterberg 3,8,9,10, Shorená Janelidze 1, Kaj Blennow 3, Oskar Hansson 1,8,11
1Clinical Memory Research Unit, Department Of Clinical Sciences, Malmö, Lund University - Lund (Sweden), 2Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center - Amsterdam (Netherlands), 3Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), 4Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King’s College London - London (United Kingdom), 5NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, NHS Foundation - London (United Kingdom), 6Banner Sun Health Research Institute - Sun City (United States), 7Roche Diagnostics GmbH - Penzberg (Germany), 8Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 9Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square - London (United Kingdom), 10UK Dementia Research Institute at UCL - London (United Kingdom), 11Memory Clinic, Skåne University Hospital - Malmö (Sweden)
2.30 p.m

**ROUNDTABLE 1**

**Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments**

Chair: Niranjan Bose, Gates Ventures, Seattle, WA (United States)

Discussants: Howard Fillit, Alzheimer's Drug Discovery Foundation (ADDF), New York City, NY (United States); Laurence Barker, Partner in the Dementia Discovery Fund (DDF), London (United Kingdom); Phillip Scheltens, LSP Dementia Fund at EQT Life, Alzheimer Centre Amsterdam (University Medical Centre Amsterdam, Amsterdam (The Netherlands); Susan Catalano, CODA Biotherapeutics, San Francisco, CA (United States)

3.00 p.m

**ORAL COMMUNICATIONS**

Chairs: Elaine Peskind, University of Washington School of Medicine - Seattle, WA (United States), Eric Reiman, Banner Alzheimer's Institute Phoenix, AZ (United States)

3.00 p.m

**OC20 - Systemic inflammation and reduced cerebral AB clearance triggered by pancreatic amylin**

Florin Despa 1, Nirmal Verma 1, Edric Winford 1, Peter Nelson 1, Gregory Jicha 1, Larry Goldstein 1, Claire Troakes 2, Henrik Zetterberg 3, John Hardy 3, Tammamyn Lashley 1

1University Of Kentucky - Lexington (United States), 2King’s College London - London (United Kingdom), 3Dementia Research Institute at UCL - London (United Kingdom)

3.15 p.m

**OC21 - Prazosin for Agitation in Alzheimer’s Disease: PEACE-AD**

Elaine Peskind 1, Murray Raskind 2, Ronald Thomas 3, Gregory Jicha 4, Neela Patel 5, Amy Pierce 6, Sharon Brangman 7, Mary Sano 8, Jeffrey Kaye 9, Miranda Lim 9, Michael Au-Yeung 9, Michelle Herman 9, Gabriel Leger 9, Karen Messer 9, Howard Feldman 9

1VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC), Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), 2VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC) and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), 3Departments of Family Medicine and Neurosciences, University of California San Diego - La Jolla (United States), 4Department of Neurology, University of Kentucky - Lexington (United States), 5Department of Family and Community Medicine, UF Health San Antonio - San Antonio (United States), 6Department of Neurology, OHSU School of Medicine - Portland (United States), 7Department of Geriatrics, SUNY Upstate Medical University - Syracuse (United States), 8Department of Psychiatry, Mount Sinai School of Medicine - New York (United States), 9Department of Neurosciences, University of California San Diego - La Jolla (United States)

3.30 p.m

**OC22 - Demographic Analysis of Industry Sponsored Alzheimer’s Disease Trial Populations in the United States**

Stephen Peroutka 1 - 1PPD, Part Of Thermo Fisher Scientific - Carmel, CA (United States)

3.45 p.m

**OC23 - Plasma Biomarker Findings from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease Colombia Trial**

Eric M. Reiman 1, Francisco Lopera 2, Silvia Rios-Romenets 2, Courtney Schiffman 3, Derrek Hibar 4, Gwendlyn Kollmorgen 4, Margarita Giraldo 5, Natalia Acosta 5, Alejandro Espinosa 5, Gustavo Villegas 5, Claudia Muñoz 5, Laura Serna 5, Karina Herrera 5, Yi Su 6, Robert Alexander 4

1Banner Alzheimer’s Institute - Phoenix, Arizona (United States), 2Neurosciences Group of Antioquia, University of Antioquia - Medellin (Colombia), 3Genentech, Inc., - South San Francisco, CA (United States), 4Roche Diagnostics GmbH - Mannheim (Germany)

4.00 p.m

Coffee break and poster session

Yosemite/Imperial Ballroom & Registration area - Tower 2

4.30 p.m

**LATE BREAKING ORAL COMMUNICATIONS**

Chairs: Michelle Farrell, Massachusetts General Hospital - Boston, MA (United States), Howard Fillit, Alzheimer’s Drug Discovery Foundation (ADDF) - New York City, NY (United States)

4.30 p.m

**LB8 - Top Line Data of ANAVEX®2-73 (blarcamesine) Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2b/3 in Patients with Early Alzheimer’s Disease (AD)**

Stephen Macfarlane 1, Timo Grimmer 2, Terence O’Brien 3, Edward Hammond 4, Walter Kaufmann 4, Emmanuel Fadiran 4, Christopher Missling 4

1Hammoncare - Melbourne (Australia), 2THU Munich - Munich (Germany), 3Monash University, Alfred Health - Melbourne (Australia), 4Anavex Life Sciences - New York (United States)
4:45 p.m  
LB9 - Higher sensitivity amyloid-PET detection of the earliest focal beta-amyloid accumulation using spatial extent
Michelle E. Farrell 1, Emma G. Thibault 1, J. Alex Becker 1, Julie C. Price 1, Kuang Gong 1, Aaron P. Schultz 1, Michael J Properzi 1, Rachel F Buckley 1,2, Heidi I.L. Jacobs 1, Bernard J. Hanseeuw 1,2, Reisa A. Sperling 1,2, Keith A. Johnson 1,2
1Massachusetts General Hospital - Boston, Ma (United States), 2Brigham & Women’s Hospital - Boston, Ma (United States), 3Cliniques Universitaires Saint-Luc, Université Catholique de Louvain - Brussels (Belgium)

5.00 p.m  
LB10 - Sample size estimates for preclinical AD intervention trials based on Wisconsin Registry for Alzheimer’s Prevention Longitudinal PET amyloid, plasma P-tau217, and cognitive assessment data
Rebecca Langhough Koscik 1, Derek Norton 1, Tobey Betthauser 1, Lianlian Du 1, Erin Jonaitis 1, Karly Cody 1, Bruce Hermann 1, Kimberly Mueller 1, Rick Chappell 1, Bradley Christian 1, Shorenna Janelidze 1, Niklas Mattsson-Carlsson 1, Oskar Hansson 1, Sterling Johnson 1
1University of Wisconsin SMPH - Madison (United States)

5:15 p.m  
LB11 - Cerebrospinal Fluid Biomarker Effects From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease: Results From the PEGASUS Trial
Steven E. Arnold 1,2, Newman Knowlton 3, Victoria J. Williams 4, Jeffrey M. Burns 5, Monica Crane 6, Alison J. Mcmanus 1, Sanjeev N. Vaishnavi 7, Zoe Arvanitakis 8, Judith Neugroschl 9, Karen Bell 10, Bianca A. Trombetta 11, Becky C. Carlyle 12,13, Rudolph E. Tanzi 13,14, Kent Leslie 15,16
1Department of Neurology, Massachusetts General Hospital, Boston, MA, USA - Boston (United States), 2Harvard Medical School, Boston, MA, USA - Boston (United States), 3Pentara Corporation, Millcreek, UT, USA - Millcreek (United States), 4Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA - Madison (United States), 5University of Kansas Alzheimer’s Disease Center, Kansas City, KS, USA - Kansas City (United States), 6Genesis Neuroscience Clinic, Knoxville, TN, USA - Knoxville (United States), 7Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA - Philadelphia (United States), 8Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL, USA - Chicago (United States), 9Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA - New York (United States), 10Department of Neurology, Columbia University, New York, NY, USA - New York (United States), 11Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, England, United Kingdom - England (United Kingdom), 12Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; 2Harvard Medical School, Boston, MA, USA - Boston (United States), 13Harvard Medical School, Boston, MA, USA - Boston (United Kingdom), 14Department of Neurology, Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Hospital, Harvard University, Boston, MA, USA - Boston (United States), 15Amylyx Pharmaceuticals, Inc., Cambridge, MA, USA - Cambridge (United States), 16Present address: Division of Biology and Biological Engineering Graduate Program, California Institute of Technology, Pasadena, CA, USA - Pasadena (United States)

5:30 p.m  
End of the Conference Day
Friday, DECEMBER 2

08.00 a.m Welcome coffee - NEW this year at CTAD > Poster Walking Tour Yosemite/Imperial Ballroom & Registration area - Tower 2

09.00 a.m KEYNOTE 4 Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease
Introduction: Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, CA (USA)
Roger Nitsch, Neurimmune, Schlieren (Switzerland)

09.20 a.m LATE BREAKING ORAL COMMUNICATIONS Chairs: Sandrine Andrieu, INSERM - Toulouse (France), Rachel Schindler, R. Schindler Consulting, New York City, NY (United States)

09.20 a.m LB12 - Use of a Blood-Based Biomarker Test Impacts Clinical Decision Making Among Neurologists Evaluating Patients With Symptoms of Cognitive Impairment
Joel Braunstein 1, Mark Monane 1, Kim Johnson 2, B. J. Snider 3, Raymond Scott Turner 4, Jonathan Drake 5, Daniel Jacobs 6, Julia Ortega 7, Joni Henderson 1, Tim West 1
1CZN Diagnostics - St Louis (United States), 2Duke University - Durham (United States), 3Washington University - St Louis (United States), 4Washington University - Washington (United States), 5Lifespan - Providence (United States), 6Neurological Services of Orlando - Orlando (United States)

09.35 a.m LB13 - Phase 1 pharmacokinetic and CNS target engagement properties of the orally administered O-GlcNAcase inhibitor ASN51 in humans
Ryan Schubert 1, Rolf Pokorny 1, Bruno Permanne 1, Pearl Fang 1, Vanessa Teachout 1, Maud Nény 1, Solenne Ousson 1, Jennifer Hantson 1, Astrid Sand 1, Ruhi Ahmed 1, Manfred Schneider 1, Jean-Francois Staallert 1, Anna Quattropani 1, Eric Yuen 1, Dirk Beher 1
1Asceneuron, Lausanne (Switzerland)

09.50 a.m LB14 - Analysis of 15 software pipelines for validation of [18F]florbetaben PET quantitation
Aleksandar Jovalekic 1, Nuria Ria-Vellve 1, Norman Koglin 1, Mariana Lagos Quintana 1, Aaron Nelson 1, Markus Diemling 1, Johan Lilja 3, Juan Pablo Gomez Gonzalez 4, Vincent Dore 5, Pierrick Bourgeat 5, Alex Whittington 6, Roger Gunn 6, Andrew Stephens 1, Santiago Bullich 1
1Life Molecular Imaging - Berlin (Germany), 2MIM Software - Cleveland (United States), 3Hermes Medical Solutions - Stockholm (Sweden), 4QuBiotech - A Coruna (Spain), 5CSIRO - Brisbane (Australia), 6Invicro - London (United Kingdom)

10.05 a.m LB15 - Results from a clinical Study of an Anti-Galectin-3 Monoclonal antibody in Patients with Moderate to Severe Alzheimer’s Disease
Dongxu Sun 1, George Haig 1, Suhail Rasool 1
1Truebinding Inc - Foster City (United States)

10.20 a.m Coffee break and poster session Yosemite/Imperial Ballroom & Registration area - Tower 2

10.45 a.m ROUNDTABLE 2 The Alzheimer’s disease Patient Pathway from a sex and gender lens
Chair: Frances Catherine Quevenco 1,2
Discussants: Maria Carmela Tartaglia 3, Heather Snyder 4, Phyllis Ferrell 5, Pernille Poulsen 6, Antonella Santuccione Chadha 1,2
1Roche (Switzerland), 2Women’s Brain Project (Switzerland), 3University Of Toronto (Canada), 4Alzheimer’s Association (United States), 5Eli Lilly (United States), 6Novo Nordisk (Denmark), 7Altoida (United States)

11.15 a.m ORAL COMMUNICATIONS’ FOCUS SESSION: Interim or preliminary data and study design
Chairs: Susan Abushakra, Alzheon, Inc - Framingham, MA (United States), Nicola Spotorno, Lund University - Lund (Sweden)

11.15 a.m OC24 - Neuroimaging Data From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
Kaya Jordan 1, Kennedy Mahdavi 1,2, Jonathan Haroon 1, Elisabeth Rindner 1, Margaret Zielinski 1, Victoria Venkatraman 1,2, Sergio Becerra 2, Dayan Goodenowe 3, Clarence Ahlem 4, Christopher Reading 4, Joseph Palumbo 4, Bijan Pourat 5, Sheldon Jordan 1,2
1The Regenesis Project - Santa Monica (United States), 2Synaptec Network - Santa Monica (United States), 3Synaptec Sciences USA LLC - Temecula (United States), 4Biovie Inc. - Carson City (United States), 5Pourat MD - Beverly Hills (United States)
**Friday, DECEMBER 2**

**11.25 a.m**

**OC25** - HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer’s disease with AGB101: Baseline Tau and MRI imaging characteristics

Richard Mohs 1, Sharon Rosenzweig-Lipson 1, Arnold Bakker 2, Elizabeth Chang 2, Nisha Rani 2, Russell Barton 1, Michela Gallagher 1, 2

1AgeneBio, Inc - Baltimore (United States), 2Johns Hopkins University - Baltimore (United States)

**11.35 a.m**

**OC26** - Design of the ABCA1 agonist CS6253 Phase 1 SAD and MAD study in male and female, APOE4 and non-APOE4 carriers to assess safety, PK and biomarker efficacy

Jan Johansson 1, Hussein Yassine 2, Danny Michaelson 1, Henrik Zetterberg 1, Jeffrey Cummings 1, Bengt Winblad 6

1Artery Therapeutics, Inc - San Ramon (United States), 2USC - Los Angeles (United States), 3Tel Aviv University - Tel Aviv (Israel), 4U of Gothenburg - Gothenburg (Sweden), 5U Nevada Las Vegas - Las Vegas (United States), 6Karolinska Insitute - Stockholm (Sweden)

**11.45 a.m**

**OC27** - Significant Effects of Oral ALZ-801 on Plasma Biomarkers of Alzheimer’s Disease: 12-Month Interim Analysis of Phase 2 Biomarker Study in APOE4 Carriers with Early AD

Susan Abushakra 1, John Hey 1, Kaj Blennow 2, Jakub Hort 4, Katerina Sheardova 5, Niels Prins 6, Sterre Rutgers 6, Paul Dautzenberg 7, Ladislav Pazdera 8, Patrick Kesslak 1, Aidan Power 1, Martin Tolar 1

1Alzheon Inc. - Framingham, Ma (United States), 2Gothenburg University, Institute of Neuroscience & Physiology - Molndal (Sweden), 3Amsterdam University Medical Center - Amsterdam (Netherlands), 4Charles University Dept. of Neurology - Prague (Czech Republic), 5St. Anne University Hospital & International Clinical Research Center - Brno (Czech Republic), 6Brain Research Center - Amsterdam (Netherlands), 7Brain Research Center - Den Bosch (Netherlands), 8Vestra Research Clinic - Rychnov Nad Kněžnou (Czech Republic)

**11.55 a.m**

**OC28** - Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease

Nicola Spotorno 1, Olof Strandberg 1, Geraline Vis 2, 3, Erik Stomrud 1, Markus Nilsson 2, 4, Oskar Hansson 1

1Clinical Memory Research Unit, Department Of Clinical Sciences, Lund University - Lund (Sweden), 2Diagnostic Radiology, Institute For Clinical Sciences, Lund University - Lund (Sweden), 3Memory Clinic, Skåne University Hospital - Malmö (Sweden), 4Memory Clinic, Skåne University Hospital - Malmö (Sweden)

**12.05 p.m**

Lunch on your own and poster session

**1.05 p.m**

**ORAL COMMUNICATIONS**

**1.05 p.m**

**OC29** - A brief, automated speech-based screener for mild cognitive impairment to support online recruitment at scale

Caroline Skirrow 1, Jack Weston 1, Marton Meszaros 1, Udeepa Meepegama 1, Emil Fristed 1

1Novoic - London (United Kingdom)

**1.20 p.m**

**OC30** - Aβ-structure as Precise Risk Plasma Biomarker for Future Conversion to Alzheimer’s Disease 17 Years in Advance

Klaus Gerwert 1, 2

1Ruhr-University Bochum - Bochum (Germany), 2Center for Protein Diagnostics (ProDi) - Bochum (Germany)

**1.35 p.m**

**ORAL COMMUNICATIONS’ FOCUS SESSION: Clinical Trials Phase 1 Results**

Chairs: Suzanne Hendrix, Pentara Corporation - Salt Lake City, UT (United States and Peter Ljubenkov, UCSF Memory and Aging Center San Francisco, CA (United States)

**1.35 p.m**

**OC31** - NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease

Daniel Mikol 1, Judy Toews 1, Martin Farlow 2, Bruce Lamb 2, George Perry 3, Reisa Sperling 4, Michael Weiner 5, Henrik Zetterberg 6, Jeffrey Cummings 7

1Neuro - Vancouver (Canada), 2Indiana University School Of Medicine - Indianapolis (United States), 3University Of Texas, San Antonio - San Antonio (United States), 4Harvard Medical School - Cambridge (United States), 5University Of California, San Francisco - San Francisco (United States), 6University Of Gothenburg - Gothenburg (Sweden), 7University Of Nevada, Las Vegas - Las Vegas (United States)
1.45 p.m

OC32 – Introduction to the Veri-T trial: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Verdiperstat in Patients with svPPA Due to FTLD-TDP
Peter Ljubenkov 1, Adam Staffaroni 1, Lawren Vandevrede 1, Julio Rojas-Martinez 1, Mary Koestler 1, Anton Porsteinsson 2, Maria B. Pascual 1, Joseph Masdeu 1, Ian Grant 1, David Irwin 1, David Knopman 6, Robert Bowser 7, Murray Grossman 5, Irfan Qureshi 8, Adam Boxer 1
1UCSF Memory and Aging Center - San Francisco (United States), 2University of Rochester - Rochester (United States), 3Houston Methodist - Houston (United States), 4Northwestern University - Chicago (United States), 5University of Pennsylvania - Philadelphia (United States), 6Mayo Clinic Rochester - Rochester (United States), 7Barrow Neurological Institute - Phoenix (United States), 8Biohaven Pharmaceuticals - New Haven (United States)

1.55 p.m

OC33 – A Phase 1, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Biochemical Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer’s Disease – Interim Data
Michael Kaplitt 1, Philip Leopold 2, Evan Noch 3, Jana Ivanidze 4, Levi Chazen 4, Ronald Crystal 2, Stephen Kaminsky 2, Haley Bowe 2, Mei Wang 2, Douglas Ballon 4, Jonathan Dyke 4, Dolan Sondhi 2, Sam Gandy 5, Gina Giannantoni-Ibelli 6, Jay Barth 6
1Department of Neurological Surgery, Weill Cornell Medical College - New York (United States), 2Department of Genetic Medicine, Weill Cornell Medical College - New York (United States), 3Department of Neurology, Weill Cornell Medical College - New York (United States), 4Department of Radiology, Weill Cornell Medical College - New York (United States), 5Departments of Neurology and Psychiatry, Icahn School of Medicine at Mt Sinai - New York (United States), 6LEXEO Therapeutics, Inc. - New York (United States)

2.05 p.m

ORAL COMMUNICATIONS

Chairs: Nicola Coley, INSERM - Toulouse [France] and Michael Donohue, Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego, CA (United States)

2.05 p.m

OC34 – Preliminary evidence for reliability and validity of the Interpersonal Functioning and Daily Activities Questionnaire (IFDAQ) in the A4/LEARN pre-randomization sample
Chris Edgar 1, Rebecca Amariglio 1, Jordan Barbone 3, Julie Chandler 4, Stephen Coons 5, Michael Donohue 6, William Lenderking 7, Reisa Sperling 8
1Cogstate - London (United Kingdom), 2Departments of Neurology, Brigham and Women’s Hospital and Massachusetts General Hospital, Harvard Medical School - Boston (United States), 3Cogstate - New Haven (United States), 4Eli Lilly and Company - Indianapolis (United States), 5Clinical Outcome Assessment Program, Critical Path Institute - Tuscon (United States), 6Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States), 7Patient-centered Research, Evidera - Bethesda (United States), 8Department of Neurology, Brigham and Women’s Hospital - Boston (United States)

2.20 p.m

OC35 – APOE-Targeted Epigenome Therapy for Alzheimer’s Disease
Boris Kantor 1, 2, Omit Chiba-Falek 1, 2
1Duke University - Durham (United States), 2CLAIRigene LLC - Durham (United States), 3CLAIRigene - Durham (United States)

2.35 p.m

OC36 – Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance
Alexa Pichet Binette 1, Shorenna Janelidze 1, Nicholas Cullen 1, Jeffrey L. Dage 2, Randall J. Bateman 3, Henrik Zetterberg 4, 5, Kaj Bliennow 4, Erik Stomrud 1, Niklas Mattsson-Carlsgren 1, Oskar Hansson 1
1Clinical Memory Research Unit, Faculty Of Medicine, Lund University - Lund (Sweden), 2Department Of Neurology, Indiana University School Of Medicine - Indianapolis (United States), 3Department Of Neurology, Washington University School Of Medicine - St. Louis (United States), 4Department Of Psychiatry And Neurochemistry, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), 5UK Dementia Research Institute, University College London - London (United Kingdom)

2.50 p.m

OC37 – Aducanumab and lecanemab label insoluble, fibrillar, diffusible Aβ aggregates in aqueous extracts of human Alzheimer disease brain
Andrew M. Stern 1, Angela L. Meunier 1, Wen Liu 1, Maria Ericsson 2, Dennis J. Selkoe 2
1Ann Romney Center For Neurologic Diseases, Brigham And Women’s Hospital, Harvard Medical School - Boston (United States), 2Harvard Medical School Electron Microscopy Core - Boston (United States)

3.05 p.m

Coffee break and poster session
Yosemite/Imperial Ballroom & Registration area - Tower 2
3.35 p.m  **LATE BREAKING ORAL COMMUNICATION**
Chairs: Francesca Cormack, Cambridge Cognition - Cambridge (United Kingdom), Jacques Touchon, University of Montpellier Montpellier (France)

**LB16 - Phase 1 Preventive Adjuvanted Tau Vaccine, AV-1980R**
Lon Schneider 1, Anahit Ghichikyan 2, Robert Alexander 3, Henrik Zetterberg 3, Eric Reiman 3, Duygu Tosun 4, Michael Agadjanyan 2
1USC - Los Angeles (United States), 2Institute for Molecular Medicine - Huntington Beach (United States), 3Banner Alzheimer’s Institute - Phoenix (United States), 4University of California San Francisco - San Francisco (United States)

3.50 p.m  **ORAL COMMUNICATIONS**

3.50 p.m  **OC38 - A multimodal clinical and lifestyle intervention induces multiomic systemic effects and improves cognitive outcomes in Alzheimer’s disease**
Jared C. Roach 1, Lance E. Edens 1, Sophiya Rajbhandari 1, Junko Hara 2, Jennifer Bramen 3,4, Molly K. Rapozo 5, Cory Funk 1, William R. Shankle 6,7,2,8, Leroy Hood 1
1Institute For Systems Biology - Seattle, Washington (United States), 2Pickup Family Neurosciences Institute, Hoag Memorial Hospital Presbyterian - Newport Beach, California (United States), 3Pacific Brain Health Center, Pacific Neuroscience Institute - Santa Monica, California (United States), 4Department of Translational Neurosciences and Neurotherapeutics, Saint John’s Cancer Institute - Santa Monica, California (United States), 5Providence St. Joseph Health - Renton, Washington (United States), 6Shankle Clinic - Newport Beach, California (United States), 7Department of Cognitive Sciences, University of California - Irvine, California (United States), 8EMBIC Corporation - Newport Beach, California (United States)

4.05 p.m  **OC39 - Advantages of next generation SupraAntigen® platform liposomal vaccines to immunize against pathological targets of Alzheimer’s disease**
Marija Vukicevic 1, Emma Fiorini 1, David Hickman 1, Rakel Carpintero 2, Marcela Rincon 2, Maria Pilar Lopez-Deber 2, Maxime Ayer 2, Stefanie Siegert 2, Chiara Babolin 2, Eva Gollwitzer 2, Saskia Delpretti-Anex 2, Piergiorgio Donati 2, Johannes Streffer 2,1, Andrea Pfeifer 2, Marie Kosco-Vilbois 2
1Ac Immune SA - Lausanne (Switzerland), 2AC Immune SA - Lausanne (Switzerland), 3University of Antwerp - Antwerpen (Belgium)

4.20 p.m  **OC40 - U-p53AZ in prognostication of early onset Alzheimer’s disease up to 6 years in advance of the clinical diagnosis**
Simona Piccirella 1, Leander Van Neste 2, Christofer Fowler 3, Colin Masters 3, Jurgen Fripp 5, James D. Doecke 4, Chengjie Xiong 5, Daniela Uberti 4, Paul Kinnon 1, Sam Aquis 3
1Diadem SpA - Brescia (Italy), 2Halixo BV - Hoegaarden (Belgium), 3The Florey Institute of Neuroscience and Mental Health - Parkville (Australia), 4The Australian e-Health Research Centre, CSIRO - Herston (Australia), 5Washington University School of Medicine, Division of Biostatistics - St. Louis (United States), 6Department of Molecular and Translational Medicine, University of Brescia - Brescia (Italy), 7Diadem US - Boston (United States)

4.35 p.m  **OC41 - iWHELD: An RCT of a Novel Digital Non-Pharmacological Intervention to Improve Quality of Life and Reduce Antipsychotics in 741 People Living in Nursing Homes During the COVID-19 Pandemic**
Clive Ballard 1, Joanne Mcdermid 1, Adrienne Sweetnam 1
1University of Exeter - Exeter (United Kingdom)

4.50 p.m  **OC42 - Making digital measures fit-for-purpose in Alzheimer’s trials**
Francesca Cormack 1, Jennifer Sorinas 2, Claire Meunier 1
1Cambridge Cognition - Cambridge (United Kingdom), 2Novartis - Basel (Switzerland), 3DiMe - San Francisco (United States)

5.05 p.m  **End of the Conference Day**
POSTER PRESENTATIONS presented in San Francisco and available on the CTAD22 digital platform
POSTERS PRESENTATIONS

All posters are available in Pdf format at all times on the CTAD22 digital platform.

Poster presentations presented onsite in San Francisco are indicated with this icon:

Tuesday, November 29 at 4 p.m to Wednesday, November 30 at 6 p.m

- THEME: Clinical Trials: Methodology P001 to LP14
- THEME: New Therapies and Clinical Trials P024 to LP25
- THEME: Clinical Trials: Results P034 to LP44
- THEME: Beyond Amyloid and Tau: Emerging Solutions P050 to LP49

Thursday, December 1st from 8 a.m to 6 p.m

- THEME: Clinical Trials Imaging P069 to LP62
- THEME: Clinical Trials: Biomarkers including plasma P090 to LP84A
- THEME: Cognitive and Functional Endpoints P126 to LP89A

Friday, December 2nd from 8 a.m to 5 p.m

- THEME: Cognitive assessment and clinical trials P141 to LP92
- THEME: Behavioral disorders and clinical trials P169 to LP93
- THEME: Health economics and clinical trials P172 to LP95
- THEME: Epidemiology and clinical trials P176 to LP96
- THEME: Animal Models and Clinical Trials P187 to LP98
- THEME: Proof of Concept/Translational research for Alzheimer Drug Development interventions P191 to LP105A
- THEME: Digital health/E-trials P205 to LP109
- THEME: AD clinical trials and COVID-19 LP110
Feasibility of virtual amyloid PET disclosure with cognitively unimpaired research participants
Claire Erickson 1, Nathaniel Chin 1, Hannah Rosario 1, Amanda Peterson 1, Sterling Johnson 1, Lindsay Clark 1
1University Of Wisconsin-Madison - Madison (United States)

Using common-close trial designs for efficiently detecting slowing of progression in Alzheimer’s disease
Lars Lau Rakel 1, Jeffrey Cummings 2
1Novo Nordisk - Saborg (Denmark), 2Chambers-Grundy Center For Transformative Neuroscience, Pam Quirk Brain Health And Biomarker Laboratory, Department Of Brain Health, School Of Integrated Health Sciences, University Of Nevada Las Vegas (unlv) - Las Vegas (United States)

Evaluating KarXT (xanomeline–trospium) as a treatment for psychosis associated with Alzheimer’s disease dementia: design of the phase 3, ADEPT-1, relapse prevention study
Carolyn Watson 1, Jeffrey Cummings 2, George Grossberg 3, Minsu Kang 1, Ronald Marcus 1
1Karuna Therapeutics - Boston (United States), 2University Of Nevada Las Vegas School Of Integrated Health Sciences - Las Vegas (United States), 3Saint Louis University School Of Medicine - Saint Louis (United States)

Number of Days Between Initial Contact and In-Person Visit Predict Attendance Rates for Potential Alzheimer’s Disease Trial Participants
Sarah Stanley 1, Gabriela Munoz 1, Miriam Evans 1, Jenicka Engler 1, Stephanie Rutick 1
1Adams Clinical - Watertown (United States)

Power analysis of a prognostic enrichment procedure based on AD Course Map, a simulation study
Etienne Maheux 1, Igor Koval 1, Juliette Orthold 1, Colin Birkenbihl 2, Vincent Bouteloup 2, Stanley Durrleman 2
1Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, CNRS, Inria, Inserm, AP-HP Hôpital de la Pitié Salpêtrière, Paris (France), 2Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Sant Augustin (Germany), 3Université de Bordeaux, Inserm 1219, CIC1401-EC - Bordeaux (France)

Implementing Novel Clinical Trial Designs in Dementia with Lewy Bodies: A Roadmap to Personalized Medicine
Carla Abdelnour 1, Jon B. Toledo 2, Daniel Ferreira 3, Federic Rodriguez-Porcel 3, Parichita Choudhury 3, Maureen Okafor 6, Sonja Scholz 7, Bradley Boeve 5, Irene Litvan 3, James Leverenz 5, Laura Bonannn 10, John-Paul Taylor 11, Simon J. G. Lewis 12, Dag Aarsland 13, Kathleen Poston 1
1Neurology And Neurological Sciences Department, Stanford University - Palo Alto (United States), 2Department Of Neurology University Of Florida College Of Medicine - Gainesville (United States), 3Division Of Clinical Geriatrics, Department Of Neurobiology, Care Sciences And Society, Karolinska Institute - Stockholm (Sweden), 4Department Of Neurology, Medical University Of South Carolina - Charleston (United States), 5Department Of Neurology, Mayo Clinic - Rochester (United States), 6Department Of Neurology, Emory University School Of Medicine - Atlanta (United States), 7Neurodegenerative Diseases Research Unit, National Institute Of Neurological Disorders And Stroke. Laboratory Of Neurogenetics, National Institute On Aging - Bethesda (United States), 8Parkinson and Other Movement Disorders Center, Department of Neurosciences, University Of California San Diego - La Jolla (United States), 9Lou Ruvo Center for Brain Health, Neurological Institute, and Department of Neurology, Cleveland Clinic - Cleveland (United States), 10Department Of Neuroscience Imaging and Clinical Sciences and CESI, University G d’Annunzio of Chieti-Pescara - Chieti (Italy), 11Translational and Clinical Research Institute, Newcastle University - Newcastle (United Kingdom), 12Forefront Parkinson’s Disease Research Clinic, Brain And Mind Centre, University Of Sydney - Camperdown Nsw 2050 (Australia), 13Institute Of Psychiatry, Psychology, & Neuroscience, King’s College London - London (United Kingdom)

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is commonly misdiagnosed as Alzheimer’s disease (AD) and Frontotemporal Dementia (FTD)
Spyros Papapetropoulos 1, Angela Pontius 1, Samantha Zappia 1, Matthew Brennan 2, Leslie Lehey 2
1Vigil Neuroscience - Cambridge (United States), 2Consultant To Vigil Neuroscience - Cambridge (United States)

Update on the TOGETHER study: a patient- and investigator-blind, randomized, placebo-controlled study evaluating the efficacy, safety and tolerability of bepranemab, UCB0107, in prodromal-to-mild Alzheimer’s disease
Matthew E. Barton 1, Bart Van Den Steen 2, Hans L. G. Van Tricht 2, William Byrnes 1, Fiona E. Purcell 3, Sarah Ann Southcott 3, Daniel Raby 3, Yaroslav I. Starshinov 3, Colin Ewen 2
1UCB Pharma - Raleigh, North Carolina (United States), 2UCB Pharma - Brussels (Belgium), 3ICON plc - Dublin (Ireland)

The impact of erratic changes on 1 year change in CDR-SB. An exploratory analysis
Alan Kott 1, Xingmei Wang 2, David Miller 2
1Signant Health - Prague (Czech Republic), 2Signant Health - Blue Bell (United States)

Early Engagement with the Alzheimer’s Disease Community to Gain Insights into Designing the SKYLINE Trial for Pre-symptomatic Alzheimer’s Disease
Fiona Rose 1, Nancy Lynn 1, Jessica B. Langbaum 2, Carolyn Langlois 3, Emma Louise Dodd 1, Jannice Roeser 4, Gesine Respondek 4, Susanne Ostrowitzki 4
11Translational and Clinical Research Institute, Newcastle University - Newcastle (United Kingdom), 2Department Of Neurology University Of Florida College Of Medicine - Gainesville (United States), 3Division Of Clinical Geriatrics, Department Of Neurobiology, Care Sciences And Society, Karolinska Institute - Stockholm (Sweden), 4Department Of Neurology, Medical University Of South Carolina - Charleston (United States)

Contrasting the NIH Toolbox Emotional Battery Outcomes Between Caucasians and African American Older Adult Participants in a Randomized Clinical Trial: I-CONNECT Study
Kevin Yu 1, Lisa Silbert 1,2, Laura Struble 1, Hiroko H. Dodge 1
1NIH-Lifton Aging and Alzheimer’s Disease Center, Department of Psychology, Oregon Health & Science University, Portland, Oregon, USA - Portland (United States), 2Portland Veterans Affairs Health Care System, Portland, OR, USA - Portland (United States), 3Department of Health Behavior and Biological Sciences, School of Nursing, University of Michigan Ann Arbor, Michigan, USA - Ann Arbor (United States)
P012 Development and Feasibility of a Data-Driven Approach to Preclinical Alzheimer's Disease Clinical Trial Recruitment through Centralized Pre-screening Data Collection

Dylan Kim 2, Joshua Grill 2, Paul Aisen 1, Karin Ernst 2, Seth Gale 4, Judith Heidebrink 5, Gregory Jicha 5, Gustavo Jimenez-Maggiora 2, Leigh Johnson 7, Elaine Peskind 4, Raymond Scott Turner 2, David Sultzer 2, Shunnan Wang 3, Reisa Sperling 4, Rema Raman 5
1Department of Neurology, Massachusetts General Hospital - Boston (United States), 2Institute for Memory Impairments and Neurological Disorders, Department of Psychiatry and Human Behavior, University of California Irvine - Irvine (United States), 3Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), 4Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), 5Department of Neurology, University of Michigan - Ann Arbor (United States), 6Sands-Brown Center on Aging, University of Kentucky - Lexington (United States), 7Institute for Translational Research, University of North Texas Health Science Center - Fort Worth (United States), 8VA Northwest Mental Illness Research, Education, and Clinical Center (MIRECC), VA Puget Sound Health Care System - Seattle (United States), 9Department of Neurology, Georgetown University Medical Center - Washington D.C. (United States)

P013 Design of Pragmatic Trials for Interventions Targeting Cognitive Decline: Benchmarks from the COcoa Supplement and Multivitamin Outcomes Study of the Mind (COSMOS-Mind)

Mark Espeland 2, Joann Manson 3, Dave Rapp 4, Howard Sesso 5, Sarah Gaussoin 6, Sally Shumaker 7, Laura Baker 8
1Wake Forest School of Medicine - Winston-Salem (United States), 2Brigham and Women's Hospital - Boston (United States), 3New England Research Institutes - Waltham (United States), 4Harvard Pilgrim Health Care - Boston (United States), 5Northeastern University - Boston (United States), 6University of California, San Francisco - San Francisco (United States), 7Johns Hopkins University School of Medicine - Baltimore (United States), 8Wake Forest School of Medicine - Winston-Salem (United States)

P014 Use of the Digit Symbol Substitution Test (DSST) as an entry criterion for a cognitive study of a β2-AR agonist

Gabriel Vargas 3, Renee Martin 1, Peter Butera 1, Judy Reynolds 1, Tim Anderson 2, Aliya Asher 3, Erik Buntinx 4, Anthony Ford 1, John Harrison 1
1CuraSen - San Carlos (United States), 2New Zealand Brain Research Institute - Christchurch (New Zealand), 3MAC Clinical Research - Manchester (United Kingdom), 4Anima Research Center - Aiken (Belgium), 5Metis Cognition - Kilmarnock (United Kingdom)

P016 Enhancing Recruitment of Underrepresented Communities with the Deployment of a Mobile Research Unit

Jill Smith 1, John Dwyer 2, Dawn Batchuluun 3, Tamiko Magee Rodgers 4, Leigh Zisko 1
1Global Alzheimer’s Platform Foundation - Washington D.C. (United States)

P017 Genotypic effects of the TOMM40’523 variant and APOE on longitudinal cognitive change over 4 years: The TOMMORROW Study

Haotian Zou 1, Sheng Luo 2, Michael W. Lutz 2, David A. Bennett 3, Brenda L. Plassman 3, Kathleen A. Welsh-Bohmer 2
1University of North Carolina-Chapel Hill - Chapel Hill (United States), 2Duke University - Durham (United States), 3University of California, San Francisco - San Francisco (United States)

P018 Racial/Ethnic Group Differences in Response Rate to a Mail Invitation to Participate in a Lifestyle Intervention Trial to Prevent Cognitive Decline (U.S. POINTER Trial)

Valory Pavlik 1, Melissa Yu 2, Ashley Alexander 3, John Valenta 3, Richard Elbein 2, Annmarie Mcdonald 1
1Baylor College Of Medicine - Houston (United States), 2Kelsey Research Foundation - Houston (United States), 3Alzheimer's Association - Houston (United States)

P019 Development of an abbreviated pre-screening cognitive battery to enhance referral to clinical trials

Abigail O'Connell 1, Eric Fischer 1, Lauren Latham 1, Laura Baker 1, Suzanne Craft 1
1Wake Forest Alzheimer's Disease Research Center - Winston-Salem (United States)

P020 Long-Term Nicotine Treatment of Mild Impairment (The MIND Study): Baseline Characteristics and Study Progress

Paul Newhouse 1, Rema Raman 2, Andrew Saykin 1, Julie Dumas 1, Edward Levin 1, Kenneth Kellar 2, Paul Aisen 2
1Vanderbilt University - Nashville (United States), 2University of California, Los Angeles (United States)

P021 Using an end-to-end deep learning model in older adults with MCI to identify AD risk factors on chromosome 19 that exacerbate cognitive decline

Jinhyeong Bae 1, Lianna Apostolova 1, Valentin Pentchev 1, Dustin Hammers 1, Angelina Polsinelli 1, Kelly Nudelman 1, Andrew Saykin 3, Kwangskik Nho 1
1IUPUI - Indianapolis (United States), 2Baylor College Of Medicine - Houston (United States), 3Alzheimer's Association - Houston (United States)

P022 Pandemic Effects on Duplicate Subjects in Clinical Trials of Alzheimer's Disease

Thomas Shiovitz 1, Chelsea Steinmetz 2, Brittany Steinmiller 2
1California Neuroscience Research, CTsDatabase LLC - Sherman Oaks, Ca (United States), 2CTSdatabase LLC - Sherman Oaks, Ca (United States)

P023 The Time Component Test is Inherently Meaningful Because it Combines Evidence Across Outcomes to Measure the Impact of Treatment on Progression Rate in Degenerative Diseases

Samuel Dickson 1, Suzanne Hendrix 1
1Pentara Corporation - Salt Lake City (United States)

LP01 Effect of treatment with the cholinergic precursor Choline Alphoscerate in mild cognitive dysfunction (CARL): Research Protocol

Enza Trani 1, Anna Carotenuto 1, Vincenzo Andreone 1, Francesco Amenta 1
1University of Camerino - Camerino (Italy), 2Neurology Complex Unit, Cardarelli Hospital - Naples (Italy)
**A Trichotomy Method for Defining Homogeneous Subgroups in a Dementia Population**

Gary Rosenblum 1

1University of New Mexico - Albuquerque (United States)

**Compliance and satisfaction in the Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Colombia Trial**

Natalia Acosta-Baena 2, Claudia Muñoz 1, Paula Ospina 1, Sorany Del Río 1, Liliana Lopez 1, Margarita Giraldo 1, Sindy Duque 1, Alexander Navarro 1, Eric M. Reiman 2, Nan Hu 1, Kemal Asik 1, Pierre N. Tariot 1, Jessica B. Langbaum 1, Francisco Lopera 1, Silvia Rios-Romenets 1

1Grupo de Neurociencias de Antioquia (GNA), Universidad de Antioquia, Medellin, Colombia. 2Medellin (Colombia), 3Banner Alzheimer’s Institute - Phoenix (United States), 4Genentech Inc. - San Francisco (United States)

**The Global Alzheimer’s Platform Foundation’s® (GAP’s) Inclusive Research Initiative: Enhancing Recruitment of Underrepresented Communities Through Community Connectors**

Dawn Batchuluun 4, Tomiko Rodgers 1, Leigh Zisko 1, Mickee Key 1, Lisa Thurman 1, John Dwyer 1

1Global Alzheimer’s Platform Foundation - Washington (United States)

**Mitigating loss of statistical power due to outcome imbalance in clinical trials**

Angela Tam 1, 2, César Laurent 1, Christian Dansereau 1

1Perecvi Al - Montreal (Canada)

**A Seamless Phase 2A-Phase 2B Multi-Center Trial to test the Benefits of Benfotiamine on the Progression of Alzheimer’s disease (BENFO-TEAM)**

Howard Feldman 1, 2, Jose Luchinger 1, Karen Messer 2, 4, Diane Jacobs 1, 2, David Salmon 1, Carolyn Reva 1, 2, Jody Lynn Lupo 1, 2, Gary Gibson 1, 2, 6

1Department of Neurosciences, University of California San Diego - La Jolla (United States), 2Alzheimer’s Disease Cooperative Study, University of California San Diego - La Jolla (United States), 3Departments of Medicine and Epidemiology, Columbia University Irving Medical Center - New York (United States), 4Division of Biostatistics, University of California San Diego - La Jolla (United States), 5Brain and Mind Research Institute, Weil Cornell Medicine - New York (United States), 6Burke Neurological Institute - White Plains (United States)

**Simulation-based power analysis could improve the design of clinical trials in Alzheimer’s disease**

Daniel Andrews 1, 3, 4, Douglas L. Arnold 1, 3, 4, Danilo Bzdok 1, 3, 6, Simon Ducharme 7, 8, Howard Chertkow 9, 10, 11, 12, 13, D. Louis Collins 1, 2, 3

1Department of Biomedical Engineering, McGill University - Montreal (Canada), 2Department of Bioengineering, McGill University - Montreal (Canada), 3McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University - Montreal (Canada), 4Department of Neurology and Neurosurgery, McGill University - Montreal (Canada), 5NeuroRx Research - Montreal (Canada), 6Department of Psychiatry, McGill University - Montreal (Canada), 7Douglas Mental Health University Institute, McGill University - Montreal (Canada), 8Baycrest Centre for Geriatric Care - Toronto, Canada, 9Kemel Centre for Brain Health and Wellness and Anne & Allan Bank Centre for Clinical Research Trials, Baycrest - Toronto (Canada), 10Canadian Consortium on Neurodegeneration in Aging (Canada), 11Division of Neurology, Department of Medicine, University of Toronto - Toronto (Canada)

**The AlzMatch Study: Remote Plasma Acquisition to Pre-screen for Preclinical Alzheimer’s Disease Trials**

Sarah Walter 1, Rema Raman 1, Gustavo Jimenez-Maggiona 1, Robert Rissman 1, Joshua Grill 1, Jason Karlawish 1, Oliver Langford 1, Stefania Bruschi 1, Michael Donohue 1, Kevin Yarasheski 1, Michael Racke 1, Reisa Sperling 1, Jeffrey Cummings 1, Paul Aisen 1

1Alzheimer’s Therapeutic Research Institute, USC - San Diego (United States), 2University of California, Irvine - Irvine (United States), 3C2N Diagnostics - St. Louis (United States), 4University of California San Diego - La Jolla (United States), 5Brain and Mind Research Institute, Weil Cornell Medicine - New York (United States), 6Burke Neurological Institute - White Plains (United States)

**Disease Progression Modelling Identified MRI-based Subtypes with Cognitive Heterogeneity in A4 Study Preclinical Trial Cohort**

Cameron Shand 1, Neil Oxtoby 1, Michael Donohue 1, Daniel Alexander 1, Frederik Barkhof 1, 2, 3

1University College London (United Kingdom), 2Alzheimer’s Therapeutic Research Institute, University Of Southern California (United States), 3Amsterdam UMC (Netherlands)

**LatAm-FINGERS study design: a multicultural harmonization work across Latin America**

Lucia Cevelli 1, Claudia Suemoto 1, Ismael Calandri 1, Paulo Caramelli 1, Francisco Lopera 1, Ricardo Nitrini 1, Ana Luisa Sosa 1, Rosa Maria Salinas 1, Lina Marcela Vellilla 1, Monica Yassuda 1, Ricardo Francisco Allegri 1, Heather Snyder 1, Miia Kiipielt 1, Maria Carrillo 1

1Fleni - Buenos Aires (Argentina), 2Division of Geriatrics, University of Sao Paulo Medical School - Sao Paulo (Brazil), 3Behavioral and Cognitive Neurology Unit, Facultade de Medicina, Universidad Federal de Minas Gerais - Belo Horizonte (Brazil), 4Neuroscience Group of Antioquia Medical School, Antioquia University - Antioquia (Colombia), 5Department of Neurology, University of Sao Paulo School of Medicine - Sao Paulo (Brazil), 6Laboratorio de demencias del Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez - Mexico City (Mexico), 7Alzheimer’s Association - Chicago (United States), 8Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm (Sweden)

**Recruitment Accelerator for Diversity in Aging Research - Cognitive Loss and Dementia (RADAR-CLD): Perspectives on Registry Recruitment**

Mary Sano 1, Jennifer Vasconcellos 2, Margaret Sewell 3, Judith Neugroschl 3, Mari Umpierre 3, Shehan Chin 3, Sharon Brangman 4, Sarah Mcnamara 4, Nancy Smith 5, Kathy Royal 5, Mike Siplaine 2

1Cahn School of Medicine at Mount Sinai - New York City (United States), 2Recruitment Partners LLC - Columbia (United States), 3Cahn School of Medicine at Mount Sinai - New York (United States), 4Upstate Medical University - Syracuse (United States)
Physician-Driven Patient Recruitment Addresses Barriers in AD Clinical Trial Enrollment
Erin Beck 1, Micah Eimerbrink 1, Katie Tyler 1, Daniel Gautieri 1
1SiteRx - New York (United States)

A Phase 3 Clinical Trial Protocol to Evaluate the Efficacy and Safety of NA-831 In Subjects with Early Onset of Alzheimer’s Disease
Lloyd Tran 1, Markku Kurkinen 1, Fem Vu 1
1Biomed Industries, Inc. - San Jose (United States)

Development of an abbreviated pre-screening cognitive battery to enhance referral to clinical trials
Abigail O’connell 1, Eric Fischer 1, Lauren Latham 1, Laura Baker 1, Suzanne Craft 1
1Wake Forest Alzheimer’s Disease Research Center - Winston-Salem (United States)

Potential Reversal of Alzheimer’s Disease pathology by Antibody TB006 Targeting Galectin-3, a Major Cause of Oligomerization of Amyloid Proteins
Suhail Rasool 1, Jenny Johansson 1, Ludmila Voloboueva 1, Sangmi Lee 1, Nancy Lan 1, Taufeeq Ahmed 1, Dongxu Sun 1
1Truebinding Inc. - Foster City (United States)

Whole-Brain Low-Intensity Pulsed Ultrasound Therapy For Early Stage Of Alzheimer’s Disease (LIPUS-AD): A Randomized, Double-Blind, Placebo-Controlled Trial
Hiroaki Shimokawa 1,2, Tomohiko Shindo 1, Aiko Ishiki 3, Naoki Tomita 3, Kumiyo Eguchi 3, Takashi Shirato 1, Jun Takahashi 1, Kentaro Shiratsuchi 4, Satoshi Yasuda 1, Hiroyuki Ari 5
1Tohoku University Graduate School Of Medicine - Sendai (Japan), 2International University of Health and Welfare - Narita (Japan), 3Institute Of Development, Aging And Cancer, Tohoku University - Sendai (Japan), 4Sound Wave Innovation, Co. - Tokyo (Japan)

CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with mild cognitive impairment due to Alzheimer’s disease
Alan Lerner 1,2, Steven Arnold 3, Erin Maxfield 1, Aaron Koenig 1, Maria Toth 1, Brooke Fortin 1, Bianca Trombetta 3, Andrew Pieper 5,6,7,8, Curtis Tatsuoka 9, Irina Pikuleva 4
1Brain Health And Memory Center, Neurological Institute, University Hospitals Cleveland Medical Center - Cleveland (United States), 2Department of Neurology, Case Western Reserve University - Cleveland (United States), 3Department of Neurology, Case Western Reserve University - Cleveland (United States), 4AmyriAD Pharma, Inc. - Los Angeles (United States), 5Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine - Boca Raton, Fl (United States), 6Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center - Cleveland (United States), 7Institute For Transformative Molecular Medicine, Case Western Reserve University - Cleveland (United States), 8Institute Of Populational And Quantitative Health Sciences, Case Western Reserve University - Cleveland (United States)

A Phase 2 Study of the Sigma-2 Ligand CT1812 in Participants with Dementia with Lewy Bodies
James Galvin 5, Magdalena Tolea 1, Michael Grundman 2, Mary Hamby 2, Anthony Caggiano 3
1Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine - Boca Raton, Fl (United States), 2Grnd Partners - San Diego, Co (United States), 3Cognition Therapeutics - Pittsburgh, Pa (United States), 4Cognition Therapeutics - Purchase, Ny (United States)

ALZLIGHT Pilot: Preliminary Report on Safety and Feasibility From a Randomized Controlled Trial of Light-Based Brain Stimulation With 40 Hz Invisible Spectral Flickering Light in Patients With Mild-to-Moderate Alzheimer’s Disease
Mikkil Peistrup Aegger 1, Marcus Schultz Carstensen 3, Maibritt Hornig 1,2, Else Rubak Danielsen 4, Anders Olihues Baandrup 4, Mai Nguyen 5, Mark Alexander Henney 1, Christopher Ravn Boe Jensen 5, Kristoffer Hougaard Madsen 6,7, Troels Wesenberg Kjær 1,2, Kamilla Miskowiak 8,9, Paul Michael Petersen 3, Peter Hegh 1,2
1Department of Neurology, Zealand University Hospital - Roskilde (Denmark), 2Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), 3Dept. of Electrical and Photonics Engineering, Technical University of Denmark - Kgs. Lyngby (Denmark), 4Department of Radiology, Zealand University Hospital - Roskilde (Denmark), 5OptoCeutics ApS - Copenhagen (Denmark), 6Dept. of Applied Mathematics and Computer Science, Technical University of Denmark - Copenhagen (Denmark), 7Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital - Amager and Hvidovre - Copenhagen (Denmark), 8Neurocognition and Emotion in Affective Disorders (NEAD) Group, Copenhagen Affective Disorder research Centre (CADIC), Psychiatric Centre Copenhagen - Copenhagen (Denmark), 9Department of Psychology, University of Copenhagen - Copenhagen (Denmark)

Characterization of amyloid-beta protofibrils in Alzheimer’s disease brain and the unique binding properties of lecanemab
Lars Lannfelt 1, Linda Söderberg 1, Malin Johansson 1, Nicolas Fritz 1, Eleni Gkanatsiou 1, Adeline Rachalski 1, Helen Kylefjord 1, Gunilla Osswald 1, Christer Möller 1
1BioArctic AB - Stockholm (Sweden)

AD101 - the clinical profile of a new, first-in-class treatment for Alzheimer’s Disease
Jan Burmeister 1, Serge Gauthier 2, Sharon Rogers 3
1BioArctic AB - Stockholm (Sweden), 2McGill University - Montréal (Canada)
POSTER PRESENTATIONS

Tuesday, November 29 at 4 p.m
to Wednesday, November 30 at 6 p.m

P031 Impact of pimavanserin on cognitive measures in patients with neuropsychiatric manifestations of Alzheimer’s disease: results from 3 placebo-controlled clinical studies
Clive Ballard 1, Victor Abler 2, Sanjeev Pathak 2, Pierre Tariot 3, Bruce Coate 2, Ana Berrio 3, James M Youkam 3, 5, Srdjan Stankovic 2
1Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), 2ACADIA Pharmaceuticals Inc. - Princeton (United States)

P032 Impact of pimavanserin treatment on motor function in patients with neuropsychiatric manifestations of Alzheimer’s disease: results from 3 clinical studies
Daniel Weintraub 1, Victor Abler 2, Clive Ballard 1, Bruce Coate 2, Ana Berrio 3, Sanjeev Pathak 2, James M Youkam 3, Srdjan Stankovic 2
1Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), 2ACADIA Pharmaceuticals Inc. - Princeton (United States)

P033 Intravenous treatment with BRIChOS molecular chaperone designed against amyloid-β toxicity improves features of Alzheimer disease pathology in mice
Jan Johansson 1
Karolinska Institutet - Huddinge (Sweden)

LP15 Computerized Cognitive Training Restores Neural Activity within the Cognition and Apathy-related Network in Mild Cognitive Impairment
Jae Myeong Kang 1, Nambeom Kim 2, Seon Kyung Yun 1, Ha-Eun Seo 2, Sangsoon Kim 2, Seong-Jin Cho 4
1Department of Psychiatry, Gil Medical Center, Gachon University College of Medicine - Incheon (Korea, Republic of), 2Incheon (Korea, Republic of), 3Department of Biomedical Engineering Research Center, Gachon University, Incheon, Republic of Korea - Incheon (Korea, Republic of), 4School of Nursing, Seokyang University College of Nursing, Yeongwol, Republic of Korea - Yeongwol (Korea, Republic of), 5Neuroscience Research Institute, Gachon University - Incheon (Korea, Republic of), 6Department of Psychiatry, Gachon University Gil Medical Center - Incheon (Korea, Republic of), 7Department of Psychiatry, Gil Medical Center, Gachon University College of Medicine - Incheon (Korea, Republic of)

LP16 Alzheimer’s Cognitive Decline Stopped For at Least 2½ Years by In-Home Transcranial Electromagnetic Treatment
Gary Azendash 1, Haitham Abulaban 2, 3, Susan Steen 3, Ross Andel 1, Yanhong Wang 2, 4, Yun Bai 1, Rob Boranowski 1, Xiaoyang Lin 2, 4, Ning Shen 2, Ali Aljassabi 2, 4, Yiting Li 1, Chuanhai Cao 1, 3
1NeuroEM Therapeutics, Inc. - Phoenix (United States), 2Axiom Clinical Research of Florida - Tampa (United States), 3University of South Florida/Byrd Alzheimer’s Institute - Tampa (United States), 4Einstein College of Medicine, University of South Dakota - Phoenix (United States), 5MEB Brain Health Research Center, University of South Florida - Tampa (United States)

LP17 First-in-Human Clinical Trial of IBC-Ab002, a Proprietary Human anti-PD-L1 Antibody, in Persons with Early Alzheimer’s Disease: Trial Design and Objectives
Jessie Cedarbaum 1, Philip Schelten 4, Catherine Mummery 4, Carol David 4, Dalia Bracha 4, Eti Yoles 4, Kuti Baruch 4, Michal Schwartz 4
1Immunobrain Checkpoint - Woodbridge, Ct (United States), 2Amsterdam UMC, Alzheimer Center - Amsterdam (Netherlands), 3Dementia Research Centre, Institute of Neurology, University College London - London (United Kingdom), 4Neuroimmunology Laboratory - Nes Ziona (Israel), 5Weizmann Institute - Rehovot (Israel)

LP19 Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in an ongoing Phase 1/2 AD study
Terence Fisher 1, Elizabeth Evans 4, Megan Boise 1, Vikas Mishra 1, Crystal Mallow 1, Ernest Smith 1, John Leonard 1, Andrew Feigin 4, Eric Siemers 1, Elizabeth Sheldon 4, Raymond Turner 4, Martin Farlow 4, Anton Pottevinson 5, Wendy Bond 4, Maurice Zauderer 1
1Vaccines Inc. - Rochester (United States), 2Rochester University - Rochester (United States), 3NYLanpneumo Health, Inc. - Rochester (United States), 4Dementics Research Foundation - New York (United States), 5Siemens Integration LLC - Zionsville (United States), 6EM Research Institute - Atlantic (United States), 7Re-cognition Health - San Diego (United States), 8Indiana University - Indianapolis (United States), 9University of Rochester - Rochester (United States), 10Neuropsychiatric Research Center of Southwest Florida - Fort Myers (United States)

LP20 Does brain-gut microbiobiomodulation have therapeutic potential in Alzheimer’s disease? Design of a pivotal sham-controlled, randomized, double-blind, multicentric clinical investigation
Julien Delrieu 1, Aroa Relano-Gines 2, Jesse Cedarbaum 3, Catherine Mummery 4, Carol David 4, Dalia Bracha 4, Eti Yoles 4, Kuti Baruch 4, Michal Schwartz 4
1NeuroEM Therapeutics, Inc. - Phoenix (United States), 2JEM Research Institute - Atlantis (United States), 3Re-cognition Health - Fairfax (United States), 4University of Montpellier - Montpellier (France)

LP21 AC-0027875, a novel gamma-secretase modulator for the treatment of Alzheimer’s disease
Johan Sandin 1, 2, 4, Märta Dahlström 1, 2, 5, 10, 11, 1
1Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), 2ACADIA Pharmaceuticals Inc. - Princeton (United States), 3School of Medicine and Public Health, University of Wisconsin-Madison - Madison (United States), 4Wisconsin Alzheimer’s Institute, University of Wisconsin-Madison - Madison (United States), 5Wisconsin Alzheimer’s Institute Center, University of Wisconsin-Madison - Madison (United States), 6Medical College of Wisconsin-Green Bay - Madison (United States), 7Alzheimer’s Disease Research Center, University of Wisconsin-Madison - Madison (United States), 8Geriatric Research and Education and Clinical Center, William S. Middleton Memorial Veterans Hospital - Madison (United States), 9Wisconsin Alzheimer’s Institute, University of Wisconsin-Madison - Madison (United States)

LP22 Impact of Icosapent Ethyl on Alzheimer’s Disease Biomarkers in Preclinical Adults: Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid (BRAVE-EPA) Study Design and Baseline Characteristics
Carol Van Hulle 1, 2, Hannah Zylecta 1, Cole Aleshia 4, Eieran Ellison 1, Elena Beckman 1, Karen Lazar 7, Blazel Madeleine 1, Cronin Kate 1, Carey Gleason 3, Sterling Johnson 9, 1, 2, Sanjay Asthana 2, 1, 3, 10, 11, 1
1Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison - Madison (United States), 2Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin-Madison - Madison (United States), 3School of Medicine and Public Health, University of Wisconsin-Madison - Madison (United States), 4Wisconsin Alzheimer’s Institute Center, University of Wisconsin-Madison - Madison (United States), 5Medical College of Wisconsin-Green Bay - Madison (United States), 6Bold Insight - Dower’s Grove (United States), 7Exact Sciences - Madison (United States), 8Cleveland Clinic Lerner College of Medicine - Cleveland (United States), 9Wisconsin Alzheimer’s Institute, University of Wisconsin-Madison - Madison (United States), 10Geriatric Research and Education and Clinical Center, William S. Middleton Memorial Veterans Hospital - Madison (United States), 11Wisconsin Alzheimer’s Institute, University of Wisconsin-Madison - Madison (United States)

CTAD 2022 29
POSTER PRESENTATIONS

Tuesday, November 29 at 4 p.m to Wednesday, November 30 at 6 p.m

LP23 A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Pesiphen® in subjects with Mild Alzheimer’s Disease/ MCI
Douglas Galasko 1, Martin Farlow 2, Brendan Luczy 3, Lawrence Honig 4, Abhay Moghekar 4, Donald Elbert 5, Randall Bateman 6, Jeremiah Momper 1, Ronald Thomas 1, Robert Rissman 1, Archana Balasubramanian 1, Maria Maccecchini 7, Howard Feldman 1
1 UC San Diego - San Diego (United States), 2 Indiana University - Indianapolis (United States), 3 Washington University - St. Louis (United States), 4 Columbia University - New York (United States), 5 Johns Hopkins University - Baltimore (United States), 6 University of Washington - Seattle (United States), 7 Annovis Pharmaceuticals - Bernwyn (United States)

LP24 Preclinical characterization of ACD056, a cognitive enhancer in clinical development for the treatment of cognitive dysfunction in Alzheimer’s disease, demonstrates increased plasticity, neuroprotection and a possible disease modifying effect
Cristina Parrado-Fernández 1, Gunnar Nordwall 1, Sanja Juric 1, Nather Madjid 1, Maria Backlund 1, Märtå Dahlström 1, Johan Sandin 2, Pontus Forsell 1
1 Alzecure Pharma AB - Huddinge (Sweden)

LP25 Overview of the preclinical program for QLX-07010 - a novel inhibitor of tau self-association
James Moo 1, Barry Levine 2, Edward Cheesman 1, Patricia Lopez 1, William Erhardt 1, Eliot Davidowitz 1
1 Oligomerix, Inc. - White Plains (United States), 2 Levine Toxic Consulting, LLC - Chicago (United States)

THEME: Clinical Trials: Results

P034 Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
Elisabeth Rindner 1, Kennedy Mahdavi 1, 2, Jonathan Haroon 1, Kaya Jordan 1, Margaret Zielinski 1, Victoria Venkatraman 2, 3, Dayan Goodenowe 4, Clarence Ahlem 5, Christopher Reading 5, Joseph Falumbo 1, Bijan Pourat 6, Sheldon Jordan 1, 3
1 The Regenesis Project - Santa Monica (United States), 2 Synaptec Network - Santa Monica (United States), 3 Synaptec Network - San Diego (United States), 4 Prodrome Sciences USA LLC - Termecula (United States), 5 Biove Inc. - Carson City (United States), 6 Pourat MD - Beverly Hills (United States)

P035 Meta-analysis of high-clearance anti-amyloid immunotherapies trials in early Alzheimer’s disease: a significant clinical effect but a low benefit/risk ratio
Nicolas Villain 1, Vincent Planche 2
1 Ap-Hp Sorbonne Université, Hôpital Pitié-Salpêtrière, Department Of Neurology, Institute Of Memory And Alzheimer’s Disease - Paris (France), 2 Univ. Bordeaux, Cns, Irmm, Umr 5293 - Bordeaux (France)

P036 LiLyPADD Trial: Targeting Hippocampal Hyperconnectivity in Cognitively Normal Older Adults at Risk for Alzheimer’s Disease with AG8101
Shi-Jiang Li 1, Arnold Bakker 2, Yang Wang 1, B. Doug Ward 1, Shelby Schold 1, Piero Antuono 1, Elias Granadillo 1, Malgorzata Franczak 1, Joseph Goveas 1
1 Medical College Of Wisconsin, 2 Johns Hopkins University

P037 Planning the next generation of Alzheimer’s Disease clinical trials using diverse patient-level database from the Critical Path for Alzheimer’s Disease (CPAD) Consortium
Sudhir Swakumaran 1, Nicholas Cullen 1, Zihan Cui 1, Eileen Priest 1, Corissa Lau 1, Hazel White 1, Michael Irizarry 2, Klaus Romero 1, Yashmin Karten 1
1 Critical Path Institute - Tucson (United States), 2 Eisai Inc. - Nutley (United States)

P038 Critical Path for Alzheimer’s Disease (CPAD) Consortium: Accelerating and de-risking therapeutic development in AD by building regulatory decision-making tools
Sudhir Swakumaran 1, Nicholas Cullen 1, Corissa Lau 1, Eileen Priest 1, Hazel White 1, Michael Irizarry 2, Klaus Romero 1, Yashmin Karten 1
1 Critical Path Institute - Tucson (United States), 2 Eisai Inc. - Nutley (United States)

P039 Effectiveness of a digitally supported care management program for family and other informal dementia caregivers: baseline data and first results from the GAIN randomized
Ingo Klimann 1, Olga Klein 1, Jochen René Thyrian 1, Melanie Boekholt 2, Stefan Teipel 1, Wolfgang Hoffmann 1
1 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/ Greifswald And University Medical Center Rostock, Department Psychosomatics And Psychotherapy - Rostock (Germany), 2 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/ Greifswald - Rostock (Germany), 3 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/ Greifswald - Greifswald (Germany), 4 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/ Greifswald And University Hospital Greifswald, Institut For Community Medicine - Greifswald (Germany)

P040 Repeat IV and SC dosing of the Anti-Sortilin Antibody AL101
Michael Ward 1, Felix Yeh 1, Lovingly Park 1, Daniel Maslyar 1, Yijie Liao 1, Hua Long 1, Hernan Picard 1, Michael Kurnellas 1, Mayura Vadhavkar 1, Amber Silva 1
1 Alector, Inc. - South San Francisco (United States)

P041 SAL-AD: A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer’s Disease
Peter Liubenkov 1, Lawrence Vandevoorde 1, Rojas Rojas 1, Madison Honey 1, Argentina Lario Lago 1, Richard Tsai 1, Mary Koestler 1, Reneaud La Joie 1, Keith Alan Johnson 1, Li Gan 3, Stephanie Lessig 3, James Brewer 4, Howard Feldman 6, Charlotte Trounissen 7, Adam Bocher 1
1 UCSF Memory and Aging Center - San Francisco (United States), 2 Amsterdam UMC - Amsterdam (Netherlands), 3 Denali Therapeutics - San Francisco (United States), 4 Harvard Medical School - Boston (United States), 5 Weill Cornell Medical College - New York (United States), 6 UC San Diego - San Diego (United States), 7 Annovis Pharmaceuticals - Bernwyn (United States)
P042 Early experience with home administration of subcutaneous gantenerumab by study partner (non-professional care partner) in the GRADUATION study
Richard Perry 1, Frank Boess 2, Marzia Scelsi 3, Timo Grimmer 4, Rafael Arroyo 5, Christopher Lane 3, Claire Lansdall 3, Janice Smith 2
1Imperial College London - London (United Kingdom), 2F. Hoffmann-La Roche Ltd - Basel (Switzerland), 3Roche Products Ltd - Welwyn Garden City (United Kingdom), 4Klinikum rechts der Isar, Technical University of Munich - Munich (Germany), 5Quirinsalud Madrid University Hospital - Madrid (Spain)

P043 A Phase 1b study to evaluate the safety, tolerability and pharmacodynamics of PRI-002 in MCI and mild AD
Oliver Peters 1, Nicoleta-Carmen Cosma 1, Janine Kutschke 1, Dieter Willbold 1
1Charité – Berlin (Germany)

P044 Enabling subcutaneous dosing of gantenerumab in Alzheimer’s Disease
Beate Bittner 1, Dietmar Schwab 1, Agnes Portron 1, Dominik Lott 1, Frank Boess 1, Rémy Kohler 1, Jakub Wojtowicz 1, Carsten Hofmann 1
1F. Hoffmann-La Roche Ltd - Basel (Switzerland)

P045 The Internet-Based Conversational Engagement Clinical Trial (I-CONNECT) in Socially Isolated Adults 75+ Years Old: Primary Analyses Results
Hiroko Dodge 1, Patrick Pruitt 1, Kexin Yu 1, Chao-Yi Wu 1, Jeffrey Kaye 1, Lisa Silbert 1, I-Connect-Conect-Team 1
1Oregon Health & Science University - Portland (United States)

P046 Computerized Games versus Crosswords Training in Mild Cognitive Impairment
Davangere Devanand 1, Terry Goldberg 1, Min Qian 1, Murali Doraiswamy 2
1Columbia University Medical Center - New York (United States), 2Duke University - Durham (United States)

P047 Pimavanserin and cardiovascular/electrocardiogram safety in patients with Alzheimer’s disease
Pierre Tariot 1, Victor Ahler 1, Sanjeev Pathak 1, Bruce Coate 1, Mary Ellen Turner 2
1Bannerga Alzheimer’s Institute and University of Arizona College of Medicine - Phoenix, Az (United States), 2Acadia Pharmaceuticals Inc. - San Diego, Ca (United States)

P048 The effects of the novel phosphodiesterase 9 (PDE9) inhibitor EZ027 (irsenontrine) on CSF gCMB, additional CSF and plasma biomarkers, and clinical outcomes in amyloid positive and amyloid negative patients with Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD)
Pallavi Sachdev 1, Kate Pinner 1, Theresa Devins 1, Larisa Reyderman 1, David Li 1, Shobha Dhadda 1, Lynn Kramer 1, Akihiko Koyama 1, Michael Irizarry 1, Steven Hersch 1
1Eisai Inc. - Nutley (United States), 2Eisai Ltd. - Hatfield (United Kingdom)

P049 Clinical Activity of the p38k kinase inhibitor neflamapimod on verbal list learning may be tau pathology dependent in dementia with Lewy bodies (DLB)
John Alam 1, Jennifer Conway 1, Hui-May Chu 1, Kelly Blackburn 1
1EFi Pharma, Inc - Boston (United States), 2Anoixis Corporation - Natick (United States)

LP26 Final 4 years results of the clinical trial ASCOMALVA
Anna Carotenuto 1, Angiola Fasanaro 1, Enea Traini 1, Francesco Amenta 1
1University of Camerino - Camerino (Italy)

LP27 Age-dependent effects of the p75 modulator LMTTA-31 on Alzheimer’s disease biomarkers in a 26-week safety and exploratory endpoint trial
Hayley Shanks 1, Stephen Massa 2, 3, Manfred Windisch 4, Anne Bojesson-Hanson 5, Frank Longo 6, Taylor Schmitz 1
1Western University - London (Canada), 2University of California San Francisco - San Francisco (United States), 3SFVAHCS - San Francisco (United States), 4Neurosccs - Graz (Austria), 5Karolinska University Hospital - Stockholm (Sweden), 6PharmatrophiX - Menlo Park (United States)

LP28 Clinical phase Ib data of the orally available anti-prion compound HO2 that disassembles Aβ oligomers into Aβ monomers
Dieter Willbold 1, 2, 3, Nicoleta Carmen Cosma 4, Janine Kutschke 1, Oliver Peters 4
1Institute of Biological Information Processing (IBI-7), Forschungszentrum Jülich - Jülich (Germany), 2Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf - Düsseldorf (Germany), 3Priavoid GmbH - Düsseldorf (Germany), 4Department of Psychiatry and Psychotherapy, CampusBenjamin Franklin, Charité Berlin - Berlin (Germany)

LP29 Late-life depression, subjective cognitive decline, and their additive risk in incidence of dementia: A nationwide longitudinal study
Sung Yong Park 1, Won Myung Bahk 2, Sheng-Min Wang 2, Hyun Kook Lim 2, Young-Joon Kwon 2, Bo Hyun Yoon 3, Kwang Hun Lee 5, Sang Yeol Lee 4, Moon-Doo Kim 7, Beom Woo Nam 8, Eun Sung Lim 9
1Key hospital - Uwang Si (Korea, Republic of), 2Yeouido St. Mary's Hospital - Seoul (Korea, Republic of), 3Soonchunhyang University Cheonan Hospital - Cheonan (Korea, Republic of), 4Naju National Hospital - Naju (Korea, Republic of), 5College of Medicine, Dongguk University - Gyeongju (Korea, Republic of), 6Wonkwang University Hospital - Iksan (Korea, Republic of), 7Jeju National University School of Medicine - Jeju (Korea, Republic of), 8Department of Psychiatry, Chungju (Korea, Republic of), 9Department of Psychiatry, Shinsegae Hya Hospital - Kimje (Korea, Republic of)

LP31 Efficacy and safety of benfotiamine plus donepezil for the treatment of patients with mild-to-moderate Alzheimer's disease in a phase 2 clinical trial
Xiaoli Pan 1, Qianhua Zhao 2, Shaoming Sang 1, Chunjiu Zhong 1
1Zhongshan Hospital, Fudan University - Shanghai (China), 2Huashan Hospital, Fudan University - Shanghai (China)
LP32 VIVIAD, A Phase 2b Study Investigating Varoglutamstat in Patients with MCI and Mild AD: Update on Dose Selection and Interim Blinded Safety Results
Frank Weber 1, Michael Schaeffer 2
1CMO Vivoryon Therapeutics N.V. - München (Germany), 2CBV Vivoryon Therapeutics N.V. - München (Germany)

LP33 Quantitative EEG results from a multiple ascending dose study in healthy volunteers with NeuroRestore ACD856, a positive modulator of Neurotrophin Trk-receptors
Martin Jönsson 1, Kristin Önnestam 1, Boel Nilsson 1, Matthias Rother 1, Erik Rein-Hedin 2, Peter Anderer 3, Manuel Kemethofer 3, Magnus Halldin 1, Pontus Forsell 3, Gunnar Nordvall 1, Johan Sandin 1, Märta Segerdahl 1
1AlzCure Pharma AB - Huddinge (Sweden), 2CTC Clinical Trial Consultants AB - Uppsala (Sweden), 3The Siesta Group Schlafanalyse GmbH - Vienna (Austria)

LP34 A Randomized Double-Blind Study to Assess the Skin Irritation and Sensitization Potential of Once-Weekly Donepezil Transdermal Delivery System
Marwan Sabbagh 1, Philip Mathew 2, Alan Blau 2
1Barrow Neurological Institute - Phoenix (United States), 2Novum Pharmaceutical Research Services - Toronto (Canada), 3Corium Inc - Grand Rapids (United States)

LP36 ABvac40 elicits a predominantly Th2 immune response that supports its excellent safety profile
María Montañés 1, Carlos Martín-Fortún 1, Sergio Castillo 1, Elisabeth Molina 1, Jose Terencio 1, Manuel Sarasa 1
1Arcelon Biotech-Grifols - Zaragoza (Spain)

LP37 Cy6463 administration in healthy participants was associated with improvements in Alzheimer’s disease-relevant biomarkers based on a systematic analysis of multiple Phase 1 clinical trials using KEM® eXplainable AI
Martin Kindermans 1, Hichem Chakroun 1, Jennifer Chickering 2, Chad Glasser 2, Pablo Iriso 1, Frederic Parmentier 1, Todd Milne 2, Phebe Wilson 2, Mohammad Afzhar 1
1Aria Pharma - Paris (France), 2Cylerion - Cambridge (United States)

LP38 A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy
Philippe Verwaerde 1, Noelle Callizot 1, Susanna Del Signore 1, Aurelien Blondel 1, Cecilia Estrella 1
1Alzprotect - Loos (France)

LP39 Three-year omega-3 PUFA trial targeting cerebral white matter lesions and integrity breakdown in older adults: ApoE stratified and exploratory results
Gene Bowman 1, Charles Murchison 2, Lisa Silbert 3, Hiroko Dodge 4, Kristen Hagen 4, David Lahna 4, Harris William 5, Jeffrey Kaye 6, Joseph Quinn 6, Lynne Shinto 6
1McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital and Harvard Medical School - Boston (United States), 2Department of Biostatistics, University of Alabama at Birmingham - Birmingham (United States), 3Department of Neurology, Oregon Health & Science University and Veterans Affairs Portland Health Care System - Portland (United States), 4Department of Neurology, Oregon Health & Science University - Portland (United States), 5Department of Internal Medicine, University of South Dakota School of Medicine and Fatty Acid Research Institute - Sioux Falls (United States)

LP40 Accounting for Disease Modification in Models of Cost Effectiveness of MABs Such As Lecanemab and Donanemab
Suzanne Hendrix 1, Craig Mallincrodt 1, Samuel Dickson 1
1Pentara Corporation - Millcreek (United States)

LP41 Effectiveness of Digital-Based Multidomain Intervention for Mild Cognitive Impairment
Michael D. Patterson 1, Jacklyn Leonard 1, Syheeda B. Jabar 1, Yuri G. Rykov 1, Bikram A Gangwar 1, Jeremy Yee 1, Nagaendran Kandiah 2, Kok Pin Ng 2
1Neurologie Therapeutics - Singapore (Singapore), 2Lee Kong Chian School of Medicine - Singapore (Singapore), 3National Neuroscience Institute - Singapore (Singapore)

LP42 The SENSE-Cog trial: A Europe-wide randomised controlled trial of hearing and vision augmentation in dementia
Inacema Leno 1, Elizabeth Camacho 2, Nathalie Chaghi-Bloissoir 3, Anna Pavlina Charalambous 4, John-Paul Connelly 5, Fofi Constantinidou 5, Renaud David 6, Rachel A Elliott 2, Eric Frison 3, Mark Hann 4, Alison Holden 2, Sean P Kenny 6, Brian A Lawlor 7, Julie Longobardi 8, Antonios M Politis 7, Martin Kindermans 1, Hichem Chakroun 1, Jennifer Chickering 2, Chad Glasser 2, Pablo Iriso 1, Frederic Parmentier 1, Todd Milne 2, Phebe Wilson 2, Mohammad Afzhar 1
1Ariana Pharma - Paris (France), 2Cyclerion - Cambridge (United States), 3Araclon Biotech-Grifols - Zaragoza (Spain), 4Ariana Pharma - Paris (France), 5Department of Neurology, Oregon Health & Science University and Veterans Affairs Portland Health Care System - Portland (United States), 6Department of Neurology, Oregon Health & Science University - Portland (United States), 7Department of Internal Medicine, University of South Dakota School of Medicine and Fatty Acid Research Institute - Sioux Falls (United States)

LP43 MRI changes following treatment of GLP-1 analogue, liraglutide, in patients with Alzheimer’s disease (ELAD Study)
Paul Edison 1, Gracia Daniela Fenninnella 1, Ritche Craig 1, Nowell Joseph 1, Livingston Nicholas 1, Zuzana Walker 1, Ridha Basil 4, Archer Hilary 5, Karim Salmon 6, Tadros George 1, Kortangent Paul 1, Holscher Christian 1, Hinz Rainer 1, Passmore Peter 10, Ballard Clive 11
1Imperial College London - London (United Kingdom), 2The university of Edinburgh - Edinburgh (United Kingdom), 3University College London - London (United Kingdom), 4Brighton and Sussex University Hospitals NHS Trust - Brighton (United Kingdom), 5University of Bristol - University Of Bristol (United Kingdom), 6Lancashire NHS Trust - Lancashire (United Kingdom), 7Birmingham University Hospitals NHS Foundation Trust - Birmingham (United Kingdom), 8Helen University of Chinese Medicine - Henan (China), 9University of Manchester - Manchester (United Kingdom), 10University of Exeter - Exeter (United Kingdom), 11Greek Association of Alzheimer’s Disease and Related Disorders - Thessaloniki (Greece)

LP44 The effects of Pomegranate Seed Oil on Mild Cognitive Impairment
Thanos Chatzikostopoulos 1, Magda Tsofali 1
1Greek Association of Alzheimer’s Disease and Related Disorders - Thessaloniki (Greece)
Serum levels of glycan epitope correlate with tau and predict progression to dementia in combination with APOE4 allele status

Robin Tyuee Zhou,1 Davide Liborio Vetanro,1 Giulia Grandi,1 Bentg Winblad,1 Lars Jernberg1, Sophia Schedin-Weiss1
1Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet - Solna (Sweden), 2Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University - Stockholm (Sweden)

Serum proBDNF predicts memory gains after lifestyle changes in elderly persons - A subgroup analysis among adherent participants in the FINGER study

Anna Matton,1 Krist hr Håkansson1, Julen Goicoeia1, Makrina Danilidou1, Tiia Ngandu2, Gorka Gerenu1, Alina Solomon1, Hilika Soininen1, Tiina Laatikainen1, Miia Kivipelto1
1Karolinska Institutet - Solna (Sweden), 2Finnish Institute on Health and Welfare - Helsinki (Finland), 3University of Eastern Finland - Kuopio (Finland)

Evaluation of long-term safety and compliance to a multimodal intervention for up to 8 years in mild cognitive impairment / prodromal Alzheimer's disease: data from the randomised controlled LipiDiDiet trial

Tobias Hartmann2, Alina Solomon3,4,5, Pieter Visser6,7, Kai Blennew8,9, Miia Kivipelto10,11,12, Hilika Soininen12,10
2Deutsches Institut für Altersprävention, Saarland University - Homburg (Germany), 3Experimental Neurology - Hamburg (Germany), 4Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland), 5Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden), 6Clinical Trials Unit, Theme Aging, Karolinska University Hospital - Huddinge (Sweden), 7Department of Neurology, Alzheimer Center, VU University Medical Center - Amsterdam (Netherlands), 8Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht - Maastricht (Netherlands), 9Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg - Mölndal (Sweden), 10Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 11Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland), 12Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden), 13Neurocenter, Department of Neurology, Kuopio University Hospital - Kuopio (Finland)

Serum proBDNF predicts memory gains after lifestyle changes in elderly persons - A subgroup analysis among adherent participants in the FINGER study

Anna Matton,1 Krist hr Håkansson1, Julen Goicoeia1, Makrina Danilidou1, Tiia Ngandu2, Gorka Gerenu1, Alina Solomon1, Hilika Soininen1, Tiina Laatikainen1, Miia Kivipelto1
1Karolinska Institutet - Solna (Sweden), 2Finnish Institute on Health and Welfare - Helsinki (Finland), 3University of Eastern Finland - Kuopio (Finland)

Optimizing detection of prodromal Alzheimer disease in mild cognitive impairment – a 4-year cerebrospinal fluid study of mild behavioral impairment in ADNI and MEMENTO

Zahinor Ismail1, Rebeca Leon1, Byron Creese1, Clive Ballard1, Philippe Robert1, Eric E. Smith1
1University of Calgary - Calgary (Canada), 2Hotchkiss Brain Institute - Calgary (Canada), 3University of Exeter - Exeter (United Kingdom), 4Université Côte d’Azur - Nice (France)

Comparison of cytokine profile in positive adults with and negative protein biomarkers Aβ42, p-Tau, t-Tau and p-Tau /Aβ42 ratio

Ivonne Carolina Bolanos Burgos1,2,3,4, Gabriela Tome Oliveira Engelmann1,2,5,6, Erika Oliveira Hansen7, Natalia Silva Dias2,5, André Teixeira Carvalho8, Daniela Valadão9,10, Débora Miranda2,11, Marco Aurélio Romano Silva2,10,11, Bernardo Mattos Viana2,5,8,9, Maria Aparecida Camargos Bicalho1,2,3,4,5
1University of Calga - Calga (Canada), 2Hotchkiss Brain Institute - Calga (Canada), 3University of Exeter - Exeter (United Kingdom), 4Université Côte d’Azur - Nice (France)

Early Detection of Alzheimer's Disease using microRNAs

Bruno Steinkrus1, Marco Heuvelman1, Jeffrey L Cummings2, Jean Manson1, Craig Ritchie1
1Hummingbird Diagnostics - Heidelberg (Germany), 2Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas - Las Vegas (United States), 3Centre for Clinical Brain Sciences, The University of Edinburgh - Edinburgh (United Kingdom)
**POSTER PRESENTATIONS**

**Wednesday, December 1st from 8 a.m to 6 p.m**

**THEME:** Clinical Trials Imaging

**P069**
*Do the radiomics or structural and functional magnetic resonance imaging give additional information to predict brain amyloid positivity?*

Yoojin Lee 1, Sungyang Jo 1, Jae-Hong Lee 1
1Asan Medical Center - Seoul (Korea, Republic of)

**P070**
*Differential effects of cardiometabolic syndrome on brain age in relation to sex and ethnicity*

Sung Hoon Kang 1, Mengting Liu 1, Sang Won Seo 1, Hosung Kim 2
1Department Of Neurology, Korea University Guro Hospital, Korea University College Of Medicine - Seoul (Korea, Republic of), 2Department Of Biomedical Engineering, Hanyang University - Seoul (Korea, Republic of)

**P071**
*Genome-Wide Association Study of the functional brain network for Alzheimer’s Disease*

Minji Kim 1, Jong-Min Lee 2
1Department Of Electronic Engineering, Hanyang University - Seoul (Korea, Republic of), 2Department Of Biomedical Engineering, Hanyang University - Seoul (Korea, Republic of)

**P072**
*Clinical and radiomic features for predicting the treatment response of repetitive transcranial magnetic stimulation in major neurocognitive disorder*

Hanna Lu 1, Sandra Sau Man Chan 1, Suki Ling Ma 1, Vincent Chung Tong Mok 1, Lin Shi 1, Arthur Dun-Ping Mak 1, Linda Chiu Wa Lam 1
1The Chinese University of Hong Kong - Hong Kong (Hong Kong)

**P073**
*Association of regional amyloid burden and brain volume with cognitive performances among individuals with subjective cognitive decline*

Chonghwee Lee 1, Dong Won Yang 1, Yun Jeong Hong 2, Seonghee Ho 3, Lee Hyeong Jeong 4, Kee Hyung Park 5, Sangyoon Kim 6, Min Jeong Wang 7, Seong Hye Choi 8, Sanggyu Lee 9
1Neurology, Catholic University Of Korea, Seoul St. Mary's Hospital - Seoul (Korea, Republic of), 2Neurology, Catholic University Of Korea, Seoul St. Mary's Hospital - Uijeongbu (Korea, Republic of), 3Neurology, Changeon Hanmaem Hospital - Changwon (Korea, Republic of), 4Neurology, Woman's University School Of Medicine, Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), 5Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of), 6Neurology, Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), 7Neurology, Roa Clinic - Seongnam (Korea, Republic of), 8Neurology, Inha University School Of Medicine, Inha University Hospital - Incheon (Korea, Republic of), 9Neolab Convergence Inc. - Seoul (Korea, Republic of)

**P074**
*The role of subthreshold levels of amyloid deposition on dementia conversion-validated with ADNI*

Hyung-Ji Kim 1, Jae-Hong Lee 2
1Uijeongbu Eulji Medical Center - Uijeongbu-Si (Korea, Republic of), 2Asan Medical Center - Seoul (Korea, Republic of)

**P075**
*Evaluation of a clinically validated digital platform to provide Diffusion MRI biomarkers in Alzheimer’s disease*

Etienne Bories 1, Arthur Bezine 1, Didier Cassereau 1, Julie Rachline 1, Iyed Trimeche 1, Jean-Baptiste Martini 1, Vincent Perlbarg 1
1BRAINTALE SAS - Strasbourg (France)

**P076**
*Increase in white matter volume and myelination after 6 months of 40Hz gamma sensory stimulation therapy in patients on Alzheimer’s Disease spectrum*

Xiao Da 1, Evan Hempel 1, Holly Mrozak 1, Zach Malchano 1, Brent Vaughan 1, J. Thomas Megerian 1, Mihaly Hajas 1,2, Aylin Cimenser 1
1Cognito Therapeutics - Cambridge, Ma (United States), 2Yale University School of Medicine - New Haven, Ct (United States)

**P077**
*Summary of ACR Phantom MRI site qualification findings over 7 years and recommendations moving forward*

Luc Bracoud 1, Joomin Oh 1, Qui Cao 1, Chris Conklin 1, Madhura Ingabalikar 1, Ha Pham 2, David Scott 1, Joyce Suhy 2
1Clario (formerly Bioclinica) - Lyon (France), 2Clario (formerly Bioclinica) - San Mateo (United States)

**P078**
*Effects of Alzheimer and Lewy Body Disease Pathologies on Brain Metabolism*

Byong Seok Ye 1, Sunonen Kang 2
1MD. PhD - Seoul (Korea, Republic of), 2MD - Seoul (Korea, Republic of)

**P079**
*Reducing Sleep Apnoea for the PrEvention of Dementia (RESHAPED): The protocol of a multi-site feasibility randomised controlled trial*

Sharon Naismith 1, Camilla Hoyos 1, Craig Phillips 1, Yaffe Kristine 1, Ralph Martins 1, Nathaniel Marshall 1, Jim Lagopoulos 4, Melinda Jackson 5, Loren Mowzowski 1, Ronald Grunstein 1
1University of Sydney - Sydney (Australia), 2University of California - San Francisco (United States), 3University of Macquarie - Sydney (Australia), 4University of Sunshine Coast - Sunshine Coast (Australia), 5Monash University - Melbourne (Australia)

**P080**
*Arterial stiffness is associated with cortical tau burden*

Young Noh 1
1Gachon University Gil Medical Center - Incheon (Korea, Republic of)
P082  Application of fully automatic Hippocampal sub-field segmentation volumes to standard resolution T1 MR Imaging in Alzheimer's disease  
Richard Joules 1, Robin Wolf 2  
1 IXICO - London (United Kingdom)  

P083  Amyloid PET centoid: impact of calibration and processing steps  
Luca Pessotto 1, Mahnaz Shekari 2, Lyudmila E. Collij 1, Richard Manber 1, David Vállez García 3, Juan Domingo Gispert López 3, Robin Wolf 1  
1 IXICO - London (United Kingdom)  
2 BarcelonàBeta Brain Research Centre, Pasqual Maragall Foundation - Barcelona (Spain)  
3 Amsterdam UMC - Amsterdam (Netherlands)  

P084  Independent effects of hippocampal subfield volumes and p-tau on memory performance in clinically unimpaired older adults  
Tammy Tran 1, Alexandra Trelle 1, Wilson Edward 1, Gayle Deutsch 1, Sharon Sha 1, Katrin Andreasson 1, Valerie Carr 1, Geoffrey Kerchner 1, Elizabeth Mormino 1, Anthony Wagner 1  
1 Stanford University - Stanford (United States)  

P085  Supporting the Communication of Modern Alzheimer's Data through Augmented Reality and Web Technologies  
Tyler Ard 1, Bieńkowski Michael 1, Arthur Toga 1  
1 USC Stevens Neuroimaging and Informatics Institute - Los Angeles (United States)  

P086  Longitudinal assessment of at-risk neuroimaging markers of neuroinflammation, axonal density and demyelination as biomarkers in Alzheimer's Disease  
Maggie Roy 1, Jean-Rene Belanger 1, Matthieu Dumont 1, Jean-Christophe Houde 1, Maxime Descoteaux 1  
1 Imecka sherbrooke (Canada)  

P087  Predicting PET-determined Aβ biomarker status in Alzheimer's disease with MRI using deep convolutional neural networks  
Christopher Lew 1, Longfei Zhou 1, Maciej Mazurowski 1, Pawel Doria-nowski 1, Susan Landau 1, Jeffrey Petrella 1  
1 Duke University Medical Center - Durham (United States)  
2 University of California, Berkeley - Berkeley (United States)  
3 Duke University Medical Center - Durham (United States)  
4 Stanford ADRC - Stanford (United States)  

P088  Early [18F]-PI-2620 tau PET signal in the stages preceding AD dementia  
Christina Young 1, Hillary Vossler 1, Edward Wilson 1, Alexandra Trelle 2, Kathleen Poston 1, Michael Zeineh 1, Michael Greicius 2, Greg Zaharchuk 1, Victor Henderson 1, Anthony Wagner 1, Katrin Andreasson 1, Guido Davidzon 1, Elizabeth Mormino 1  
1 Stanford ADRC - Stanford (United States)  

P089  Amyloid and tau burden in an at-risk, cognitively unimpaired clinical trial cohort: Neuroimaging data from the U.S. POINTER trial  
Alice Murphy 1, Theresa Harrison 1, Tyler Ward 1, Prashanthi Vemuri 2, Robert Koepp 3, Samuel Lockhart 4, Mark Espeland 4, Danielle Harvey 4, Joseph Masdeu 5, Hwamee Oh 5, Darren Gitelman 6, Neelum Aggarwal 6, Laura Baker 6, Charles Decarli 7, Susan Landau 1  
1 U.C. Berkeley (United States)  
2 Mayo Clinic (United States)  
3 University of Michigan (United States)  
4 Wake Forest School of Medicine (United States)  
5 Brown University (United States)  
6 Houston Methodist (United States)  
7 Advocate Lutheran General Hospital (United States)  
8 Rush University Medical Center (United States)  

LP50  First microtubule-based PET imaging studies in cognitively normal and impaired older adult subjects—a pilot study  
Naresh Damuka 1, Bhuwanachandra Bhoopal 1, Mack Miller 1, Ivan Krizan 2, Samuel Lockhart 3, Akiva Mintz 4, Suzanne Craft 5, Kian K Solinaparam 6  
1 Wake Forest School of Medicine - Winston Salem (United States)  
2 Columbia University Medical Center - New York (United States)  

LP51  Comparative Study on the Predictive Value of Different Resting-State Functional Magnetic Resonance Imaging Parameters in Preclinical Alzheimer’s Disease  
Won-Myong Bahk 1, Young-Joon Kwon 2, Bo-Hyun Yoon 3, Kwanghun Lee 3, Sang-Yeol Lee 3, Moon-Doo Kim 3, Beomwoo Nam 4, Sung-Yong Park 4, Eunsung Lim 4, Sheng-Min Wang 4, Hyun Kook Lim 4  
1 The Catholic University of Korea - Seoul (Korea, Republic of)  
2 Soonchunhyang University - Cheonan (Korea, Republic of)  
3 Naju National Hospital - Naju (Korea, Republic of)  
4 Dongguk University - Gyeongju (Korea, Republic of)  
5 Brown University - Irvine (Korea, Republic of)  
6 Jeju National University - Jeju (Korea, Republic of)  
7 Shinsegae Hyo Hospital - Kimje (Korea, Republic of)  

LP52  Development of Random Forest Algorithm Based Prediction Model of Alzheimer’s Disease Using Neurodegeneration Pattern  
Kwanghun Lee 1, Won-Myong Bahk 2, Young-Joon Kwon 2, Bo-Hyun Yoon 3, Sang-Yeol Lee 3, Moon-Doo Kim 4, Beomwoo Nam 4, Sung-Yong Park 4, Eunsung Lim 4, Sheng-Min Wang 4, Hyun Kook Lim 4  
1 Department of Psychiatry Dongguk University Hospital - Gyeongju (Korea, Republic of)  
2 Department of Psychiatry, Yeooido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)  
3 Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of)  
4 Department of Psychiatry, Jeju National University School of Medicine - Jeju (Korea, Republic of)  
5 Department of Psychiatry, Shinsegae Hyo Hospital - Kimje (Korea, Republic of)  

LP53  Association between white matter hyperintensities (WMH) volume and cognitive function in Alzheimer’s disease  
Yoon Bo-Hyun 1, Bahk Won-Myong 2, Kwon Young-Joon 1, Lee Kwanghun 1, Lee Sang-Yeol 1, Kim Moon-Doo 4, Nam Beomwoo 2, Park Sung-Yong 4, Lim Eunsung 4  
1 Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of)  
2 Department of Psychiatry, Yeooido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)  
3 Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of)  
4 Department of Psychiatry, Jeju National University School of Medicine - Jeju (Korea, Republic of)  

Thursday, December 1st from 8 a.m to 6 p.m
LP53A  Cross sectional association between frailty and white matter hyperintensity among Alzheimer’s disease
Kim Moon-Doo 1, Bahk Won-Myong Bahk 1, Kwon Young-Joon 1, Yoon Bo-Hyun 1, Lee Kwanghun 1, Lee Sang-Yeol 1, Nam Beomwoo 1, Park Sung-Yong 1, Lim Eunsung 1
1Department of Psychiatry, Jeju National University School of Medicine - Jeju (Korea, Republic of), 2Department of Psychiatry, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), 3Department of Psychiatry, Soochunhyang University Cheonan Hospital, Soochunhyang University Cheonan (Korea, Republic of), 4Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), 5Department of Psychiatry, College of Medicine, Dongsik University - Gyeongju (Korea, Republic of), 6Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), 7Dr. Nam’s Psychiatric Clinic - Chungju (Korea, Republic of), 8Department of Psychiatry, Keyo Hospital - Uwang (Korea, Republic of), 9Department of Psychiatry, Shinsegae Hyo Hospital - Kimje(Korea, Republic of)

LP54  Clinical and biomarker characteristics of subjective cognitive decline who progressed to MCI within 24-months follow-up
Dong Won Yang 1, Chunghee Lee 1, Yun-Jeong Hong 2, Seonghee Ho 1, Jee Hyang Jeong 3, Kee Hyung Park 3, Sangyoon Kim 4, Min Jeong Wang 7, Seong Hye Choi 1, Sanggyu Lee 9
1Department of Neurology, College Of Medicine, The Catholic University Of Korea - Seoul (Korea, Republic of), 2Department of Neurology, The Catholic University Of Korea Uijeongbu St. Mary’s Hospital, Uijeongbu, Republic Of Korea - Uijeongbu (Korea, Republic of), 3Department of Neurology, Changwon Hammaeum Hospitaljeongbu, Republic Of Korea - Changwon (Korea, Republic of), 4Department of Neurology, Womans University School Of Medicine, Ewha Womans University Seoul Hospital, Changwon Hammaeum Hospitaljeongbu, Republic Of Korea - Seoul (Korea, Republic of), 5Department of Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of), 6Department of Neurology, Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Bundang (Korea, Republic of), 7Neurology, ROA Clinic - Bundang (Korea, Republic of), 8Department of Neurology, Inha University School Of Medicine, Inha University Hospital - Inchon (Korea, Republic of), 9NeolAB convergenc Inc - Seoul (Korea, Republic of)

LP55  In Vivo Head-To-Head Comparison of [18F]6TP1 and [18F]MK6240 in Alzheimer’s Disease
Matteo Tonietto 1, Cristian Constantinescu 1, Sandra Sanabria Bohorquez 1, Roger Gunn 5, David Russell 3, Edmond Teng 1, Dan Abramzon 7, Karen Pickhorn 1, Gregory Klein 1
1Hoffmann-La Roche, Ltd. - Basel (Switzerland), 2Inviroc, LLC - Needham (United States), 3Genentech, Inc. - South San Francisco (United States), 4Inviroc, LLC - London (United Kingdom), 5Inviroc, LLC - Needham (United Kingd)

LP56  Evaluating the Impact of Carotid Endarterectomy on Cognition and Hippocampal Fractional Anisotropy
Adam Bernstein 1, Juan Arias 1, Craig Weinkauf 1, Theodore Iouda 1
1University of Arizona - Tucson (United States)

LP57  New insights into the contribution of tau PET imaging in AD therapeutic trials
Julien Lagarde 1,2,3, Pauline Olivier 1, Matteo Tonietto 1,2,3, Philippe Gervais 1, Fabien Caillé 3, Martin Mousson 5, Michel Bottlaender 1,2,4, Marie Sarazin 1,7,8
1Department of Neurology of Memory and Language, GHU Paris Psychiatry & Neurosciences, Hôpital Sainte Anne - Paris (France), 2Université Paris Cité - Paris (France), 3Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEAT, CNRS, Inserm - Orsay (France), 4Research and Early Development (pRED), Hoffmann-La Roche - Basel (Switzerland), 5Centre d’Evaluation Troubles Psychiques et Vieillissement, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, Paris (France), 6Université Paris-Saclay, UNIMC, Neurospin, Joliot Institute, CEA - Gif Sur Yvette (France), 7Université Paris Cité - Paris (France), 8Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEAT, CNRS, Inserm - Orsay (France)

LP58  Methods to decrease sample size needed for longitudinal Florbetapir tau PET
Suzanne Baker 1, Pablo Aguilar Dominguez 1, Susan Landau 2, Theresa Harrison 2, Renaud Lajoie 3, Tyler Ward 2, Kailin Zhuang 2, Gil Rabinovici 3, William Jagust 2
1Lawrence Berkeley National Lab - Berkeley (United States), 2University of California, Berkeley - Berkeley (United States), 3University of California, San Francisco - San Francisco (United States)

LP59  Prevalence of microhemorrhages, superficial siderosis and other MRI abnormalities in a population of cognitively unimpaired older adults from the CHARIOPTRO study
Luc Bracoud 1,2, Chi Udeh-Momoh 1,2, Saad 1, Dimitra Kafetsouli 1, Emmett Daly 4, Onah Okoye 4, Parthenia Giannakopoulou 4, David Scott 5, Joyce Suhy 3, Susan Baker 6, Gerald Novak 6, Craig Ritchie 7, Lefkos Middleton 8, Lefkos Middleton 8
1Department of Psychiatry, College Of Medicine, The Catholic University Of Korea - Seoul (Korea, Republic of), 2Department of Psychiatry, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), 3Department of Psychiatry, Nancy University Hospital, Nancy (France), 4Age Research, School of Public Health, Imperial College of London - London (United Kingdom), 5Department of Neurology, University Of Texas Southwestern Medical Center - Dallas (United States), 6Department of Neurology, Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Bundang (Korea, Republic of), 7Department of Neurology, Inha University School Of Medicine, Inha University Hospital - Inchon (Korea, Republic of), 8Department of Psychiatry, Jeju National University School of Medicine - Jeju (Korea, Republic of)

LP60  Prediction of longitudinal change in CDR Sum of Boxes using a cortical microstructural AD signature from baseline diffusion MRI
Ged Ridgway 1, Mario Torsa 1, Dimitra Tzaferou 1, Michele Valotti 1, Ian Hardingham 1, Steven Chance 2, Adini Alzheimer’s Disease Neuroimaging Initiative 2
1Oxford Brain Diagnostics Ltd - Oxford (United Kingdom), 2Alzheimer’s Disease Neuroimaging Initiative (United States)

LP61  Cortical microstructural measures from diffusion MRI correlate with cognitive composite scores and predict their longitudinal changes
Mario Torsa 1, Ged Ridgway 1, Michele Valotti 1, Ian Hardingham 1, Steven Chance 2, Adini Alzheimer’s Disease Neuroimaging Initiative 2
1Oxford Brain Diagnostics Ltd - Oxford (United Kingdom), 2Alzheimer’s Disease Neuroimaging Initiative (United States)

LP62  APOEε4 carriership and Aβ positivity for the populational enrichment of clinical trials testing drug effects on tau tangles
João Pedro Ferrari-Souza 1,2, Pamela Ferreira 1, Bruna Bellaver 1, Guilherme Povala 1, Firoza Lussier 1, Douglas Leffia 1, Cécile Tricot 2, Joseph Thirault 2, Thomas Kairikari 1, Jean-Paul Soucy 1, Serge Gauthier 2, Eduardo Zimmer 3, Pedro Rosa-Neto 1, Tharick Pascoal 1
1University of Pittsburgh - Pittsburgh (United States), 2McGill University - Montreal (Canada), 3University of Gothenburg - Mölndal (Sweden), 4Universidade Federal do Rio Grande do Sul - Porto Alegre (Brazil)
**Theme: Clinical Trials: Biomarkers including plasma**

**P090** Impacts of amyloid burden on longitudinal cognitive declines in subjective cognitive decline: a prospective cohort study

Yun Jeong Hong 1, Dong Won Yang 2, Seonghee Ho 3, Kwonoh Park 3, Jee Hyang Jeong 4, Kee Hyung Park 5, Sangyun Kim 6, Min Jeong Wang 4, Seong Hye Choi 7, Sanggyu Lee 8

1Uijeongbu St. Mary's Hospital - Uijeongbu (Korea, Republic of), 2Seoul St. Mary's Hospital - Seoul (Korea, Republic of), 3Pusan National University Yangsan Hospital - Yangsan (Korea, Republic of), 4Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), 5Gachon University Gil Hospital - Incheon (Korea, Republic of), 6Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), 7Inha University School Of Medicine - Incheon (Korea, Republic of), 8Neolab Convergence Inc. - Seoul (Korea, Republic of)

**P091** Predictive value of plasma p-tau181 versus baseline amyloid-PET for longitudinal amyloid accumulation in asymptomatic Alzheimer's Disease

Rik Vandenberghe 1, 2, Stéffi De Meyer 1, Emma Luckett 1, Jeroen Vanbrabant 2, Jolien Schavebeke 1, Mariska Reimitz 1, Isabelle Cleyen 1, Erik Stoops 2, Eugeen Vanmehelen 2, Koen Van Laere 4

1Alzheimer Research Centre Ku Leuven, Leuven (Belgium), 2Adx Neurosciences - Zwijnaarde (Belgium), 3Laboratory For Complex Genetics - Leuven (Belgium), 4Nuclear Medicine Service, University Hospitals Leuven - Leuven (Belgium)

**P092** Blood biomarkers for Alzheimer's disease to predict dementia risk in a large clinic-based cohort: implications for clinical trials

Vincent Planche 1, Vincent Bouteloup 1, Geneviève Chêne 1, Carole Dufouil 1

1Bordeaux University - Bordeaux (France)

**P093** Independent Effect of Body Mass Index Variation on Amyloid-β Positivity

Sung Hoon Kang 1, Jong Hyuk Kim 1, Kyungja Kim 1, Sang Won Seo 3

1Department Of Neurology, Korea University Guro Hospital, Korea University College Of Medicine - Seoul (Korea, Republic of), 2Department Of Digital Health, Sahst, Sungkyunkwan University - Seoul (Korea, Republic of), 3Department Of Neurology, Samsung Medical Center, Sungkyunkwan University School Of Medicine - Seoul (Korea, Republic of)

**P094** Phase 2 study reveals an adequate PK/PD relationship of bosutinib in Dementia with Lewy Bodies and clears the path for larger Phase 2/3 investigations

Charbel Moussa 1, Fernando Pagan 2, Torres-Yaqui Yasar 3, Hebron Michaleine 1, Turner Raymond S 1, Ahn Jaeil 1

1Georgetown University Medical Center - Washington (United States), 2Medstar Georgetown Hospital - Washington (United States)

**P095** Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias

Jonathan Hanon 1, Kennedy Mahdavi 1, 2, Kaya Jordan 1, Elisabeth Rindner 1, Margaret Zielinski 1, Victoria Venkatraman 1, 2, Dayan Goodenowe 1, Kaitlyn Hofmeister 3, Clarence Ahlem 4, Christopher Reading 4, Joseph Palumbo 4, Bijan Pourat 5, Sheldon Jordan 1, 2

1The Regenesis Project - Santa Monica (United States), 2Synaptec Network - Santa Monica (United States), 3Prodrome Sciences USA LLC - Temecula (United States), 4Biovic Inc. - Carson City (United States), 5Pourat MD - Beverly Hills (United States)

**P096** Robustness of cerebrospinal fluid (CSF) amyloid-β 1–42/amyloid-β 1–40 (Aβ42/Aβ40) and phosphorylated tau/amyloid-β 1–42 (pTau/Aβ42) biomarker ratios in classification of amyloid positron emission tomography (PET) positivity in routine clinical use

Chad Logan 1, Henrik Schinke 1, Christina Rabe 1, Maryline Simon 3, Oskar Hansson 4, 5, Kaj Blennow 4, 5

1Roche Diagnostics GmbH - Penzberg (Germany), 2Genentech, Inc. - South San Francisco (United States), 3Roche Diagnostics International Ltd - Rotkreuz (Switzerland), 4Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), 5Memory Clinic, Skåne University Hospital - Malmö (Sweden)

**P097** The biomarker-based etiological diagnosis of neurocognitive disorders: the European Inter-Societal Delphi Consensus

Stefania Orini 1, 2, Cristina Festari 1, Federico Massa 1, Matteo Cotta Ramosino 3, 4, Flavio Nobili 3, 4, Giovanni Battista Frisoni 5, 10, 11 The European Inter-Societal Consensus On The Biomarker-Based Diagnosis Of Dementia

1Alzheimer’s Unit-Memory Clinic, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli - Brescia, (Italy), 2Laboratory Of Alzheimer’s Neuroimaging And Epidemiology, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, - Brescia, (Italy), 3Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dinogmi), University Of Genoa - Genoa (Italy), 4Unit Of Behavioral Neurology, IRCCS Mondino Foundation - Pavia (Italy), 5Department Of Brain And Behavioral Sciences, University Of Pavia, - Pavia, (Italy), 6Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dinogmi), University Of Genoa - Genoa (Italy), 7IRCCS Ospedale Policlinico San Martino, - Genoa (Italy), 8Laboratory Of Neuroimaging Of Aging (Janvie), University Of Geneva - Geneva (Switzerland), 9Geneva Memory Center, Department Of Rehabilitation And Geriatrics, Geneva University Hospitals, G - Geneva (Switzerland), 10The European Inter-Societal Consensus On The Biomarker-Based Diagnosis Of Dementia

**P098** Predicting amyloid positivity with blood-based biomarkers including p-tau181

Kwon Hyuk Sung 1, Lee Eun Hye 1, Park Hyun-Hee 1, Koh Seong-Ho 1

1Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine - Guri (Korea, Republic of)
**POSTER PRESENTATIONS**

**Thursday, December 1st from 8 a.m to 6 p.m**

**P099** Data-driven 18F-Flortaucipirt cut-offs for preclinical and early AD
Giulia Quattinì 1,2, Clarissa Ferrari 3, Michela Pievani 4, Federica Ribaldi 4, Szymon Tomczyk 5, Giovanni Battista Frisoni 4, Valentina Garibotto 4, Moira Marzioni 1
1Laboratory Of Alzheimer’s Neuroimaging And Epidemiology (lane), Ircs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy). 2Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy - Brescia (Italy). 3Unit Of Statistics, Ircs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy). 4Memory Clinic And Lanev-Laboratory Of Neuroimaging Of Aging, University Hospitals And University Of Geneva, Switzerland - Geneva (Switzerland).

**P100** Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimer’s Disease and Neurodegeneration stratified by sex
Irene Cumplido Mayoral 1,2,3,4,5,7, Marta Milà-Alomà 2,3,4,5,6, Luigi Lorenzini 5, Alle Mei-Jie Wink 6, Henk J.m.m. Mutsaerts 6, Sven Haller 6, Gael Chetelat 7, Frederik Barkhof 4,6, Margherita Carboni 5, Gwendyn Kollmorgen 5, Henrik Zetterberg 11,12,13,14, Kaj Blennow 11,12,13, Marc Suárez-Calvet 1,2,3,4,5,15, Verónica Vilaplana 16,17, Juan Domingo Gispert 15,16,17
1BarcelonaNeeta Brain Research Center (ibrc), Pasqual Maragall Foundation - Barcelona (Spain). 2Universitat Pompeu Fabra - Barcelona (Spain). 3CIBER Fase Fragilidad y Envejecimiento Saludable (CIBERFES) - Madrid (Spain). 4Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands). 5CIRD Centre d’Imagerie Rive Droite - Geneva (Switzerland). 6Imaging of Neurological Disorders, Institut Blood and Brain @ Caen-Normandie, Cytocan - Caen (France). 7Institutes of Neurology and Healthcare Engineering, University College London - London (United Kingdom). 8Roche Diagnostics International Ltd - Rotkreuz Zg (Switzerland). 9Roche Diagnostics GmbH - Penzberg (Germany). 10Institute of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden). 11Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden). 12Department of Neurodegenerative Disease, UCI Queen Square Institute of Neurology - London (United Kingdom). 13UK Dementia Research Institute at UCL - London (United Kingdom). 14Servei de Neurologia, Hospital del Mar - Barcelona (Spain). 15Department of Signal Theory and Communications, Universitat Politècnica de Catalunya - Barcelona (Spain). 16Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) - Madrid (Spain).

**P101** Cerebrospinal fluid placental growth factor in relation to cerebrovascular disease and diabetes in non-demented elderly
Eske Christiane Gentje 1,2, Shona Janelide 1, Danielle Van Westen 1,4, Erik Stromdor 1,5, Sebastian Palmqvist 1,5, Oskar Hansson 1,5, Niklas Mattsson-Carlsten 1,2,7
1Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden). 2Department of Internal Medicine, Skåne University Hospital - Lund (Sweden). 3Diagnostic Radiology, Department Of Clinical Sciences Lund, Lund University - Lund (Sweden). 4Imaging and Function, Skåne University Hospital - Lund (Sweden). 5Memory Clinic, Skåne University Hospital - Malmö (Sweden). 6Department of Clinical Sciences Lund, Neurology Lund University, Skåne University Hospital - Lund (Sweden). 7Wallenberg Center for Molecular Medicine, Lund University - Lund (Sweden).

**P102** Plasma AD biomarkers can Predict Hippocampal Atrophy
Hyung-Ji Kim 1,2, Jae-Hong Lee 1
1Uijeongbu Eulji Medical Center - Uijeongbu-Si (Korea, Republic of). 2Asan Medical Center - Seoul (Korea, Republic of).

**P103** Assessment of Plasma p-tau181 in TANGO, a Phase 2 study of Gosuramemab in Patients with early Alzheimer’s Disease
Julie Czerkowicz 1, Jessica Kong 1, Annie Racine 1, Carrie Rubel 1, Jessica Collins 1, Melanie Shulman 1, Danielle Graham 1, John Beaver 1, Samantha Budd Haebelen 1
1Biogen - Cambridge (United States).

**P104** Conneal confocal microscopy and MRI brain volumetry: Prognostic biomarkers for progression from mild cognitive impairment to dementia
Georgios Poniarakis 1, Rayaz Malik 1
1Weill Cornell Medicine in Qatar - Doha (Qatar).

**P105** Digerimer biomarkers for preclinical and clinical drug development in neurodegenerative disorders
Oliver Bannach 1,2, Lara Blömeke 1,2, Bettina Kass 1, Alice Chen-Plotkin 1, Oliver Peters 1, Dieter Willbold 1,2
1Forschungszentrum Jülich - Jülich (Germany). 2Alzheimers Bötting GmbH - Düsseldorf (Germany).

**P106** Exploratory study on the proteomic and transcriptomic content of plasma extracellular vesicles in AD patients
Maria Solaguren-Beascoa 1, Ana Gámiz-Valero 1,2, Ana M. Ortiz 1, Carla Minguet 1, Ricardo Gonzalo 1, Georgia Escaramis 1,2, Montserrat Costa 1, Eulàlia Martí 1,2
1Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Institut de Neurociencies, Universitat de Barcelona - Barcelona (Spain). 2Centre de Investigació Biomèdica en Red sobre Epidemiologia y Salud Pública (CIBERESP) - Barcelona (Spain). 3Grifols Bioscience Research Group - Barcelona (Spain).

**P107** Towards the development and validation of a general-purpose regulatory-grade neuroimage analysis tool
Nick Henscheid 1, Inanne Papas 2, Ryan Cabeen 2, Jagdeep Podichetty 1, Samuel Hobel 2, Christopher Weber 3, Yashmin Karten 1, Klaus Romero 1, Oliver Bannach 1,2, Lara Blömeke 1,2, Bettina Kass 1, Alice Chen-Plotkin 1, Oliver Peters 1, Dieter Willbold 1,2
1Critical Path Institute - Tucson (United States). 2University of Southern California - Los Angeles (United States). 3Alzheimer’s Association - Chicago (United States).

**P108** Comparative performance of plasma Aβ42/Aβ40 and p-tau181 for the detection of early brain amyloid deposition in individuals with subjective cognitive decline
María Pasqual-Lucas 1,2, José Antonio Allué 1, Leticia Sarasa 1, Noelia Fandos 1, Sergio Castillo 1, Jose Terencio 1, Manuel Sarasa 1, Juan Pablo Tartari 2, Ángela Sanabria 2,3, Lluís Tàrraga 2,3, Agustín Ruiz 2,3, Marta Marquié 2,3, Mercè Boada 2,3
1Araclon Biotech-Grifols - Zaragoza (Spain). 2Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya - Barcelona (Spain). 3CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III - Madrid (Spain).
POSTER PRESENTATIONS

Thursday, December 1st from 8 a.m to 6 p.m

P109  Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer’s Disease
Charisse N. Winston 1, Oliver Lanford 1, Natalie Levin 1, Rema Raman 2, Kevin Yarasheski 1, Tim West 1, Sarah Abdel-Latif 1, Michael Donohue 2, Akinori Nakamura 1, Kenji Toba 1, Colin L. Masters 1, James Doecke 1, Reisa A. Sperling 1, Paul S. Aisen 2, Robert A. Rissman 10
1Department of Neurosciences, University of California San Diego - La Jolla (United States), 2Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, University of Southern California - San Diego (United States), 3C2N Diagnostics - St. Louis (United States), 4Department of Biomarker Research, National Center for Geriatrics and Gerontology - Obu (Japan), 5National Center for Geriatrics and Gerontology, Obu, Aichi, Japan, and Tokyo Metropolitan Institute of Gerontology - Obu (Japan), 6The Florey Institute, The University of Melbourne - Parkville (Australia), 7Commonwealth Scientific and Industrial Research Organization - Herston Old (Australia), 8Harvard Medical School - Boston (United States), 9Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, University of Southern California - Los Angeles (United States), 10Department of Neurosciences, University of California San Diego and VA San Diego Healthcare System - La Jolla (United States)

P110  Myocardial sympathetic denervation biomarkers for early detection of prodromal DLB
Mee Young Park 1, Dong Sung Shin 1
1Neurology Yeungnam University Medical Center - Daegu (Korea, Republic of)

P111  pTau81 plasma biomarker performance as an inclusion criterion in the RETHINK-ALZ and REFOCUS-ALZ trials in mild-to-moderate Alzheimer’s disease
Anna Mammel 1, Pankaj Kumar 2, Lindsay Burns 1, Donald Biehl 1, Mary Encarnacion 2, Anna Cruz 2, Ging-Yuek Robin Hsiung 4, Ian Mackenzie 4, Veronica Hirsch Reinschagen 5, Ali Mousavi 2, Ryan Fortna 1, James Kupiec 1, Hans Frykman 2
1Neurocode - Bellingham, Washington (United States), 2BC Neuroimmunology - Vancouver (Canada), 3Cassava Sciences - Austin, Texas (United States), 4University of British Columbia - Vancouver (Canada), 5Northwest Pathology - Bellingham, Washington (United States)

P112  Critical evaluation and comparison of biomarker values in commercial CSF with Lumipulse® to support assay development for clinical trials
Hugo Vanderstichele 1, Malhsan Rafizadeh 1, Erika Cline 1, Johnson Derrick 1, Enca Simmons 1, Robert Dean 1, Jasna Jerecic 1
1Biomarkable - Gent (Belgium), 2Acumen Pharmaceuticals - Charlottesville (United States), 3B25 Life sciences - Indianapolis (United States)

P113  Detection of CSF alpha-synuclein in patients with prodromal Lewy body disease
Melanie Plastini 1, Carla Abdelnour 1, Marian Shahid 1, Manuel Medina 2, Nelson Kha 2, Hanna Hovren 2, Jennifer Lamoureux 2, Victor Henderson 1, Kathleen Poston 1
1Stanford University - Palo Alto (United States), 2Ampriion Clinical Laboratory - San Diego (United States)

P115  Effect of butyrylcholinesterase genotype on patients with Alzheimer’s disease treated with rivastigmine
Hoin Kim 1, So Yeon Cho 1, Geun Nam 1, Kichul Kim 1,2, Eosoo Kim 1, Jun Young Lee 2
1Emocog Inc. - Seoul (Korea, Republic of), 2Department of Psychiatry, Seoul Metropolitan Government-Seoul National University Boramae Medical Center - Seoul (Korea, Republic of), 3Department of Psychiatry, Institute of Behavioral Science in Medicine, Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine - Seoul (Korea, Republic of), 4Epi Biotech Co., Ltd. - Incheon (Korea, Republic of)

P116  Pharmacodynamic Effects of Semorinemab on Plasma and CSF Tau Biomarkers in a Phase 2 Trial in Mild-to-Moderate Alzheimer’s Disease (Lauriet)
Stephen Schauer 1, Julie Lee 1, Veronica Anania 1, Balazs Toth 1, Lee Honigberg 1, Kristin Wildsmith 1, Vidya Ramakrishnan 1, Michael Dolton 1, Sandra Sanabria Bohorquez 1, Edmond Teng 1, Cecilia Monteiro 1
1Genentech, Inc. - South San Francisco (United States), 2Alkahest, a Grifols company - San Carlos (United States), 3Grifols - Barcelona (Spain), 4Universitat Internacional de Catalunya - Barcelona (Spain), 5Universitat de Barcelona - Barcelona (Spain), 6University of Pittsburgh - Pittsburgh (United States)

P117  Novel technology platform for the direct and sensitive detection of circulating AD-related molecules in blood
Carine Lim 1
1Sumbird Bio - Singapore (Singapore)

P118  Recruitment of amyloid positive individuals and early Alzheimer’s patients in a primary care setting – results from the BioFINDER Primary Care study
Sebastian Palmqvist 1, Pontus Tideman 1, Erik Stomrud 1, Ruben Smith 1, Antoine Leuzy 1, Sadek Jafar Jasem 1, Niklas Mattsson-Carlgren 1, Anna Orduña Dolado 1, Shorena Janelidze 1, Oskar Hansson 1
1Lund University - Malmö (Sweden)

P119  Deep plasma and CSF proteomics profiling of the AMBAR study
Chunmiao (mia) Feng 1, Ricardo Gonzalez 2, Carla Minguez 2, Pilar Lafuente 2, Ana Maria Ortiz 2, Scott Lohr 3, Mercè Boada 2, Oscar López 4, Antonio Paez 2, Steven Brathwaite 1, Montserrat Costa 2, Benoit Lehallier 1
1Alkaheset, a Grifols company - San Carlos (United States), 2Grifols - Barcelona (Spain), 3Universitat Internacional de Catalunya - Barcelona (Spain), 4University of Pittsburgh - Pittsburgh (United States)

P120  Association of neighborhood-level socioeconomic disadvantage with CSF biomarkers of Alzheimer’s disease and neurodegeneration
Gilda Ennis 1, Megan Zuelsdorf 1, Ryan Powell 1, Tobey Bethausser 1, William Buckingham 1, Yue Ma 1, Carol V. Hult 1, Margherita Carboni 1, Gwendlyn Kollmorgen 1, Carey Gleason 1, Sterling Johnson 1, Kaj Blennow 1, Henrik Zetterberg 1, Amy Kind 1, Barbara Bendlin 1
1University of Wisconsin - Madison (United States), 2Roche Diagnostics International Ltd - Rotkreuz (Switzerland), 3Roche Diagnostics GmbH - Penzberg (Germany), 4University of Gothenburg - Gothenburg (Sweden)
POSTER PRESENTATIONS

Thursday, December 1st from 8 a.m to 6 p.m

LP82 The development of an automated EEG-based machine learning pipeline for the detection of Alzheimer's Disease, a proof-of-concept study for clinical trial biomarkers
Nicholas Chedid 1
1SynapseBio Inc - New York (United States)

LP83 Towards implementation of plasma phospho-tau 181 as a screening tool for patient recruitment
Andreja Emersic 1, Bjarn-Eivind Kirsebom 2, 3, Wagner S Brum 4, 5, Marianne Wettergreen 6, 7, Bengt Winblad 6, 8, Kaj Blennow 10, 11, Milica Gregoric Kramberger 1, 2, Tormod Fladby 6, 12
1Department of Neurology, University Medical Centre - Ljubljana (Slovenia), 2Department of Neurology, University Hospital of North Norway - Tromsø (Norway), 3Department of Neurology, Medical Faculty, University of Ljubljana - Ljubljana (Slovenia), 4Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Gothenburg (Sweden), 5Department of Psychology, Faculty of Health Sciences, UiT, The Arctic University of Norway - Tromsø (Norway), 6Department of Clinical Medicine, University of Oslo - Lørenskog (Norway), 7Institute of Clinical Medicine, University of Oslo - Lørenskog (Norway), 8Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics Karolinska Institutet - Stockholm (Sweden), 9Clinical Molecular Biology (EpiGen), University of Oslo - Oslo (Norway), 10Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden), 11Karolinska University Hospital - Stockholm (Sweden), 12Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Gothenburg (Sweden), 13Universidade Federal do Rio Grande do Sul (UFRGS) - Porto Alegre (Brazil)

LP84 Leukocyte-Derived Ratios Are Associated With Dementia
Yu Na Kim 1, 2, Saleena Arif 2
1Boston University - Boston (United States), 2DotHouse Health - Boston (United States)

LP84A Three group classification of participants based on fully automated plasma β-amyloid measurements to achieve high positive and negative predictive values
Kazuto Yamashita 1, Masahiro Miuara 1, Kota Nagai 2, David Verbel 3, Shigeki Iwanaga 1, Toshiyuki Sato 1, Tomokazu Yoshida 4, Atsushi Iwata 5
1Central Research Laboratories, Sysmex Corporation - Kobe (Japan), 2Japan and Asia Clinical Development Department, Eisai Co., Ltd - Tokyo (Japan), 3Biostatistics, Eisai Inc. - Nutley (United States), 4Sysmex Corporation - Kobe (Japan), 5Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of gerontology - Tokyo (Japan)

THEME: Cognitive and Functional Endpoints

P126 Visit-to-visit blood pressure variability and cognition in the SPRINT MIND trial
Isabel Sible 1, Daniel Nation 2
1Usc - Los Angeles (United States), 2Uc Irvine - Irvine (United States)

P127 Classification and Prediction of Different Cognitive Trajectories in Cognitively Normal Elderly
Young Ju Kim 1, Si Eun Kim 2, Alice Hahn 1, Soo Hyun Cho 3, Duk L Na 4, Jun Pyo Kim 1, Hyemin Jang 1, Hee Jin Kim 1, Juhee Chin 1, Sang Won Seo 1
1Samsung Medical Center - Seoul (Korea, Republic of), 2Haeundae Paik Hospital - Busan (Korea, Republic of), 3Johns Hopkins Bloomberg School Of Public Health - Baltimore (Korea, Republic of), 4Chonnam National University Hospital - Chonnam (Korea, Republic of)

P128 What's in a score: Comparing and aligning scores based on item response theory and classical test theory for the Amsterdam Instrumental Activities of Daily Living Questionnaire
Mark Dubbelman 1, Merel Postema 1, Roos Jutten 2, John Harrison 1, Craig Ritchie 3, Benjamin Schalet 4, Caroline Terwee 5, Wiesje Van Der Flier 1, Philip Scheltens 1, Sietske Sikkes 1
1Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Umc Location Vumc - Amsterdam (Netherlands), 2Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), 3Department Of Neurology, University Of Edinburgh - Edinburgh (United Kingdom), 4Department Of Medical Social Sciences, Feinberg School Of Medicine, Northwestern University - Chicago (United States), 5Amsterdam Umc Locatio Vumc, Epidemiology And Data Science, Amsterdam Umc - Amsterdam (Netherlands)

P129 Slowing of Alzheimer's Disease Progression with NeuroAiD
Christopher Li-Hsian Chen 1, Yogesh Pokharkar 2, Narayanaswamy Venkatasubramanian 3
1National University of Singapore - Singapore (Singapore), 2Singapore Clinical Research Institute - Singapore (Singapore), 3Raffles Hospital - Singapore (Singapore)

P130 A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Investigation of Safety and Efficacy of Nilotinib BE in Early Alzheimer's Disease (NILEAD)
Yasar Torres-Yaghi 1, Marwan Sabbagh 2, Chris Hoyt 3, Kimberly Guedes 3, Fernando Pagan 1, Raymond Turner 1, Jaeli Ahn 1, Charles Moussa 1
1Georgetown - Washington, DC (United States), 2Barrow - Phoenix, AZ (United States), 3Keiferx - Washington, DC (United States)
POSTER PRESENTATIONS

Thursday, December 1st from 8 a.m. to 6 p.m.

P131 Subjective illness representations in an early-stage Alzheimer’s disease population: psychometric properties of the RADIX questionnaire
Alberto Villarejo-Galende 1, Elena García-Arcelay 1, Gerard Piñol-Ripoll 1, Antonio Del Olmo-Rodriguez 1, Felix Vihuela 1, Mercè Boada 1, Emilio Franco-Macias 1, Almudena Ibáñez De La Peña 1, Mario Riverol 1, Josée Macaron 2
1Department Of Neurology, Hospital Universitario 12 De Octubre - Madrid (Spain), 2Medical Department, Roche Farma - Madrid (Spain), 3Department Of Neurology, Hospital Universitario De Santa María - Uleida (Spain), 4Department Of Neurology, Hospital Universitario Dr. Peset - Valencia (Spain), 5Department Of Neurology, Hospital Universitario Virgen Macarena - Sevilla (Spain), 6Department Of Neurology, Hospital Universitario Virgen Del Rocío - Sevilla (Spain), 7Centro De Investigación De Parkinson, Policlinica Guipúzcoa - San Sebastián (Spain), 8Department Of Neurology, Clínica Universidad De Navarra - Pamplona (Spain)

P132 Impact of Disease Progression on Dependency in Patients with Mild and Moderate Alzheimer Disease
Wenyo Ye 2, Julie Chandler 1, Xiaojuan Mi 3, Anjie Tothorn-Heidenreich 1, Joseph Johnston 1, Erin Doty 1
1Eli Lilly And Company - Indianapolis (United States), 2Atechdata Services Company - King Of Prussia (United States)

P133 The responsiveness of cognitive and functional outcome measures in preclinical Alzheimer’s disease: Implications for trial design
Mark Dubbelman 1, Heleen Hendriksen 1, Lois Ottenhoff 1, Everard Vijverberg 1, Niels Prins 2, Lior Kroeze 1, Argonde Van Harten 1, Bert Van Berckel 1, John Harrison 1, Wiesje Van Der Flier 1, Sietske Sikkes 1
1Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Umc Location Vumc - Amsterdam (Netherlands), 2Brain Research Center - Amsterdam (Netherlands)

P134 The effect of dietary habit on the progression of Alzheimer’s disease: A CREDFOS [Clinical Research Center for Dementia of South Korea] study
Yangki Min 1, Seonghye Choi 2
1Kangnam Sacred Heart Hospital, Hallym University - Seoul (Korea, Republic of), 2Inha University Medical Center - Inchon (Korea, Republic of)

P135 Length of administration of ADAS-Cog and CDR assessment impacts data quality
Barbara Echevarría 1
1WCG Clinical Endpoint Solutions - Hamilton (United States)

P136 A randomized study to evaluate the efficacy of Donepezil in improving visuospatial abilities in patients with mild cognitive impairment using eye-tracker
Kim Ko Woon 1, Wang Qi 2, Koo Se Hee 3, Shin Byoung Soo 1
1Department of Neurology, Jeonbuk National University Medical School and Hospital - Jeonju (Korea, Republic of), 2Department of Neurology, Jeonbuk National University Medical School - Jeonju (Korea, Republic of), 3Department of Neurology, Jeonbuk National University Medical School - Jeonju (Korea, Republic of), 4Department of Biomedical Research, Jeonbuk National University Hospital - Jeonju (Korea, Republic of)

P137 A Phase 2b, Randomized, Placebo-Controlled Trial to Evaluate the Effects of SAGE-718 in Patients with Alzheimer’s Disease: Study Design
Aaron Koenig 1, Tiffany Lago 1, Jason Johannessen 1, Sigui Li 1, Emily Freitag 1, Jeffrey Wald 1, Katrina Paumier 1, Michael Quirk 1, James Doherty 1
1Sage Therapeutics, Inc. - Cambridge, Massachusetts (United States)

P138 Bringing meaning to personalised Brain Health: a tool that empowers individuals to define and monitor personally meaningful change
Stina Saunders 1, David Bates 1, Ankur Bharija 2, 3, Joyce Gomes-Osman 2, 4, Saturnino Luz 1, Graciela Muniz-Terrera 1, Álvaro Pascual-Leone 2, 5, Craig Ritchie 1
1Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh (United Kingdom), 2Linus Health Inc., Boston, MA, USA - Boston (United States), 3Department of Medicine, Division of Primary Care and Population Health, Stanford Medicine, Stanford, CA, USA - Stanford (United States), 4Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA - Miami (United States), 5Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA - Boston (United States)

P139 Dementia conversion rate differences between patients with high- and low-risk amnestic mild cognitive impairment in the real-world: A prospective, multicenter, observational study
Hyemin Jang 1, Duk L. Na 2, Jay Cheol Kwon 1, Mee Young Park 3, Yeonsil Moon 3, Jung Seok Lee 4, Kyung Won Park 5, Ae Young Lee 6, Hanna Cho 7, Jae-Hong Lee 8, Byeong Chae Kim 11, Kee Hyung Park 12, Byung Chul Lee 13, Hujin Choi 14, Kim Jin 15, Na Yeon Jung 16
1Samsung Alzheimer’s Convergence Research Center, Samsung Medical Center - Seoul (Korea, Republic of), 2Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), 3Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), 4Department of Neurology, Changwon Fatima Hospital - Changwon (Korea, Republic of), 5Department of Neurology, Yeungnam University College of Medicine - Daegu (Korea, Republic of), 6Department of Neurology, Konkuk University Medical Center, Konkuk University College of Medicine - Seoul (Korea, Republic of), 7Department of Neurology, Jeju National University College of Medicine - Jeju (Korea, Republic of), 8Department of Neurosurgery, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health - Busan (Korea, Republic of), 9Department of Neurology, Chonnam National University College of Medicine - Daegu (Korea, Republic of), 10Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), 11Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine - Seoul (Korea, Republic of), 12Department of Neurology, Chonnam National University Medical School & Hospital - Gwangju (Korea, Republic of), 13Department of Neurology, College of Medicine, Gachon University Gil Hospital - Incheon (Korea, Republic of), 14Department of Neurology, Hallym University College of Medicine - Seoul (Korea, Republic of), 15Department of Neurology, Hanyang University Guri Hospital - Guri (Korea, Republic of), 16Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine - Yangsan (Korea, Republic of)

P140 Predicting tau PET signal in prodromal-to mild Alzheimer’s disease from speech biomarkers and machine learning
Mario Mina 1, Johannes Troeger 1, Louisa Schwed 1, Nicklas Ling 1, Sandra Sanabria Bohórquez 1, Somaye Hashemifar 1, Tina Boggiano 2, Edmond Teng 2
1ki:elements - Saarbruecken (Germany), 2Genentech Inc - San Francisco (United States), 3F. Hoffmann-La Roche Ltd - Basel (Switzerland)
A multicenter, Randomised, Open-label, prospective study to estimate the add-on effects of Memantine as Ebixa® Oral pump (solution) on language in moderate to severe Alzheimer’s Disease patients already receiving donepezil (ROMEO-AD)
Hee-Jin Kim 1, Hyun Jeong Han 2, Yongsoo Shim 3, Byeong C. Kim 1, Kee Hyung Park 4, So Young Moon 5, Seong Hye Choi 6, Dong Won Yang 7, Bora Yoon 8, Eun-Joo Kim 9, Jee Hyang Jeong 10, Seol-Heui Han 11
1Professor of Neurology Department of College of Medicine, Hanyang University - Seoul (Korea, Republic of), 2Department of Neurology, Myongji Hospital, Hanyang University College of Medicine - Seoul (Korea, Republic of), 3Department of Neurology, The Catholic university of Korea Eunpyeong St. Mary’s Hospital - Seoul (Korea, Republic of), 4Department of Neurology, Chonsan National University Medical School - Seoul (Korea, Republic of), 5Department of Neurology, Ajou University School of Medicine - Seoul (Korea, Republic of), 6Department of Neurology, Inha University School of Medicine - Seoul (Korea, Republic of), 7Department of Neurology, The Catholic University of Korea, Seoul St. Mary’s hospital - Seoul (Korea, Republic of), 8Department of Neurology, Konyang University College of Medicine - Seoul (Korea, Republic of), 9Department of Neurology, Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), 10Department of Neurology, Konkuk University College of Medicine - Seoul (Korea, Republic of)

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder and Early Dementia: The MEMORY Study
Michael Cronquist Christensen 1, Simon Nitschky Schmidt 1, Iria Grande 2
1H. Lundbeck A/S - Valby (Denmark), 2Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM - Barcelona (Spain)

Assessing Clinically Meaningful Functional Outcomes in Preclinical Alzheimer’s Disease
Carla Romano 1, Gerald Novak 2, Jiyoung Choi 3, Shanshan Qin 1, David Henley 2, Mike Donohue 2, Gary Romano 4, Rema Raman 2, Rebecca Amariglio 3, Paul Aisen 3, Reisa Sperling 3
1RTI-HS - Research Triangle Park (United States), 2Janssen - Titusville (United States), 3UC - San Diego (United States), 4Alector - San Francisco (United States), 5Harvard - Boston (United States)

Characterizing Cognitive Changes in Early-Stage Alzheimer’s Disease using Latent Cognitive Measures from the ADNI Dataset
Jason Bock 1,2, Junko Hara 1,2, Dennis Fortber 1, Bruce Albala 1,3,5
1Embic Corporation - Newport Beach (United States), 2Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States), 4UCI Center for Clinical Research - Irvine (United States), 5UCI School of Medicine - Irvine (United States)

Neurogenesis Hypothesis with a case study- Phase 2A Clinical Trials Results of NA-831 for the treatment of Alzheimer’s disease
Markku Kurkinen 1, Lloyd Tran 2
1Biomed Industries, Inc. - San Jose (United States)

Cognitive Composite Outcome Measures for Clinical Trials: Can You Have Too Much of a Good Thing?
Xinvan Wang 1, Diane Jacobs 1, David Salmon 1, Howard Feldman 1, Sarah Banks 1, Steven Edland 1
1University of California San Diego - La Jolla (United States)
P141  SKT Short Cognitive Performance Test for the detection of early cognitive decline – data from international validation studies
Mark Stemmler 1, 2
1University Of Erlangen-Nuremberg - Erlangen (Germany), 2Erlangen (Germany)

P142  iMPACT Cognitive Assessment: What are we measuring
James Gyorke 1, Phili Schatz 2
1Riverside Insights - Lutz (United States), 2Saint Joseph's University - Philadelphia (United States)

P143  Validation of an objective, speech-based object content score for measuring disease progression in AD
Jessica Robin 1, Mengdan Xu 1, Michael Detke 1, William Simpson 2
1Winterlight Labs - Vancouver (Canada), 2Winterlight Labs - Toronto (Canada), 3Detke Biopharma Consulting - Indianapolis (United States)

P144  Relationship between telomere shortening and early subjective depressive symptoms and cognitive complaints in older adults
Seong Ho Koh 1, Myung-Hoon Han 1, Eun-Hye Lee 1, Hyun-Hee Park 1, Seong Hye Choi 2
1Hanyang University - Seoul (Korea, Republic of), 2Inha University - Incheon (Korea, Republic of)

P145  Accuracy of automated scoring of word recall assessments
Rachel Kindellan 1, Celia Fidalgo 1, William Simpson 1, Jessica Robin 1
1Winterlight Labs - Toronto (Canada)

P147  Pre-Screening Prodromal AD Trial Populations over the Telephone Using a Speech Biomarker for Cognition — Preliminary Results from AUTONOMY Phase 2 AD Trial Recruitment
Stephen Ruhmel 1, Johannes Tröger 1, Nicklas Linz 2, Janna Herrmann 3, Mary Quiceno 1, Kai Langel 1
1Janssen Research & Development, LLC (United States), 2Winterlight Labs - Vancouver (Canada), 3Winterlight Labs - Toronto (Canada), 4Detke Biopharma Consulting - Indianapolis (United States)

P148  The difference in trajectories according to early amyloid accumulation in normal cognitive elderly
Young Ju Kim 1, Min Young Chun 1, Hyemin Jang 1, Hee Jin Kim 1, Jeong-Yeon Seo 1, Sang Won Seo 1
1Samsung Medical Center - Seoul (Korea, Republic of)

P149  Rater Error Pattern on the CDR Outcome Assessment in Alzheimer's Disease Clinical Trials
Jordan Barbone 1, Erin Barney 1, Jason Cromer 1, Robyn Leventhal 1, Lisle Kingery 1, Svenja Wacker 1
1Cogstate - New Haven (United States)

P150  Preliminary psychometric and clinical validation of information processing speed in early Alzheimer's Disease using a smartphone-based remote assessment
Arnaud M. Wolfer 1, Irma T. Kurniawan 1, Kirsten I. Taylor 1, Florian Lipsmeier 1, Thanneer M. Perumal 1
1Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 - Basel (Switzerland)

P151  Rater Error Pattern on the MMSE and ADAS-Cog Outcome Assessments in Alzheimer’s Disease Clinical Trials
Svenja Wacker 1, Jordan Barbone 1, Erin Barney 1, Jason Cromer 1, Lisle Kingery 1, Robyn Leventhal 1
1Cogstate - New Haven (United States)

P152  Preliminary psychometric and clinical validation of executive function in early Alzheimer’s diseases using a smartphone-based assessment
Irma T. Kurniawan 1, Arnaud M. Wolfer 1, Christopher Chatham 1, Eduardo Aponte 1, Stefan Holiga 1, Thanneer M. Perumal 1, Kirsten I. Taylor 1
1Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124 - Basel (Switzerland)

P153  Preliminary psychometric and clinical validation of visuospatial working memory deficits in early Alzheimer’s Disease measured with a smartphone based digital assessment
Eduardo A. Aponte 1, Kirsten I. Taylor 1, Arnaud M. Wolfer 1, Christopher Chatham 1, Thanneer M. Perumal 1
1Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124 - Basel (Switzerland)

P154  The Phase 2 LUMINARY Trial Assessing SAGE-718 in Patients with Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease
Aaron Koenig 1, Shishuka Malhotra 2, Jeffrey Wald 1, Jennifer Petrillo 1, Katrina Paumier 2, Jason Johannesen 1, Sigui Li 1, Michael Quirk 1, Emily Freitag 1, James Doherty 1
1Sage Therapeutics, Inc. - Cambridge, Massachusetts (United States), 2Neuro-Behavioral Clinical Research, Inc. - North Canton, Ohio (United States)
**POSTER PRESENTATIONS**

Friday, December 2nd from 8 a.m to 5 p.m

**P168**
A novel 2-minute high-frequency assessment of episodic memory, shows diurnality, time varying patterns in fatigue and mood which become more tightly coupled with age

Alexander Anwyl-Irvine 1, Alexander Kaula 1, Nick Taptiklis 1, Cashdollar Nathan 1, Francesca Cormack 1

1Cambridge Cognition - Cambridge (United Kingdom)

**LP90**
Achieving 98% scoring accuracy in a novel voice-based multi-day learning paradigm

Nick Taptiklis 1, Alex Kaula 1, Hayley Tseng 1, Francesca Cormack 1

1Cambridge Cognition - Cambridge (United Kingdom)

**LP91**
Sex differences in the association between tau PET and cognition in preclinical AD (A4 study)

Xin Wang 2, Erin Sundermann 2, Sarah Banks 2

2University of California, San Diego - San Diego (United States)

**LP92**
Stepped-Assessment for Cognitive Screening and Evaluation: MemTrax-CogniFit

Curtis Ashford 2, James Clifford 3, Michael Bergeron 3, Jon Andoni 4, John Ashford 5, Carlos Rodriguez 6

2MemTrax, LLC - Redwood City (United States), 3College of San Mateo - San Mateo (United States), 4University of Hartford - Hartford (United States), 5Nebriia University - Madrid (Spain), 6CogniFit, Inc. - Madrid (Spain)

**THEME: Behavioral disorders and clinical trials**

**P169**
A proof-of-concept study to evaluate efficacy of NanoLithium on the progression of Neuropsychiatric symptoms in patients with mild-to-severe Alzheimer’s disease

Maria Soto 1, Solene Guilliot 2, Pierre-Jean Ousset 1, Davide Angioni 1, Nathalie Sastre Hengan 1, Jean-Claude Maurel 2, Jacques Touchon 2

1Department Of Geriatrics, Gerontopole, University Hospital Toulouse, France - Toulouse (France), 2Medesis Pharma - Baillargues (France), 3Montpellier School Of Medicine; University Of Montpellier - Montpellier (France)

**P170**
Phase-3 Study of Masupirdine (SUVN-502), a 5-HT6 Receptor Antagonist, For the Potential Treatment of Agitation in Participants with Alzheimer’s of the Type

Jayaranjan Pradeep 1, Ravula Jyothsna 1, Jetta Satish 1, Goyal Vinod Kumar 1, Benade Vijay 1, Shinde Anil 1, Pandey Santosh Kumar 1, Subramanian Ramkumar 1, Mohammed Abdul Rasheed 1, Nirogi Ramakrishna 1

1Siven Life Sciences Ltd - Hyderabad (India)

**P171**
Safety and Tolerability of Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: Pooled Results From Three Phase III Trials

Daniel Lee 2, Mary Slomkowski 2, Nanco Heting 2, Dalei Chen 2, Klaus Larsen 2, Eva Kohegyi 2, Mary Hobart 2, Alpesh Shah 2, Alvin Estilo 2, Moeen Panni 2, Anja Farovik 2, Maia Miguelez 2, Pedro Such 2, George Grossberg 2

2Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), 1H. Lundbeck A/S - Valby, Copenhagen (Denmark), 3Department of Psychiatry and Behavioral Neuroscience at Saint Louis University School of Medicine - St Louis, Missouri (United States)

**LP93**
Effects of Brexpiprazole on Severity of Agitation in Alzheimer’s Dementia: An Analysis of Clinical Global Impression data from Two Phase III Fixed-Dose Trials

Daniel Lee 2, Mary Slomkowski 2, Nanco Heting 2, Dalei Chen 2, Klaus Larsen 2, Eva Kohegyi 2, Mary Hobart 2, Alpesh Shah 2, Alvin Estilo 2, Moeen Panni 2, Anja Farovik 2, Maia Miguelez 2, Pedro Such 2

2Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), 1H. Lundbeck A/S - Valby, Copenhagen (Denmark)

**THEME: Health economics and clinical trials**

**P172**
Health economic considerations in the development of a preventive Alzheimer’s treatment

Soeren Matkic 1, Kate Jun 1, Samantha Chu 1, Mark Hanson 1, Eric Reiman 1, Jeffrey Kordower 1

1University Of Southern California - Los Angeles (United States), 2Cornell University - Ithaca (United States), 3Banner Alzheimer’s Institute - Phoenix (United States), 4Arizona State University - Tempe (United States)

**P173**
Long-Term Care Insurance Service Utilization pattern according to clinical factors of Dementia

Jun Hong Lee 2

2National Health Insurance Service Ilsan Hospital - Goyang-Si (Korea, Republic of)

**P174**
The Impact on R&D Investment of the CMS National Coverage Determination for Amyloid-directed Monoclonal Antibodies in Alzheimer’s Disease

Duane Schul-theiss 1, Harry Bowen 2

1vital transformation - Wazembeek Oppem (Belgium), 2Queens University - Charlotte (United States)

**P175**
Bridging clinical trials and health economic models in Alzheimer’s disease

Linus Jonsson 1, Ron Handels 1, Colin Green 1

1Karolinska Institutet - Stockholm (Sweden), 2Maastricht University - Maastricht (Netherlands)
A more precise diagnosis by means of amyloid-PET contributes to delayed institutionalization, lower mortality and reduced care costs in a tertiary memory clinic setting.

**LP94**

**The Minority Report: An Update on Minority recruitment from a large site in Central Florida**

Moawen Razavi 1, William Herring 2, Cai Gillis 3, Nancy Maserejian 3, Peter Pemberton-Ross 4, Mina Nejati 5

1Schneider Institutes for Health Policy and Research, Brandeis University - Waltham (United States); 2RTI Health Solutions - Research Triangle Park (United States); 3Biogen - Boston (United States); 4Biogen - Baar (Switzerland)

**THEME: Epidemiology and clinical trials**

**P176**

**Identification of medical conditions as risk factors for mild cognitive impairment – a US claims database study**

Gang Li 1, Toschi Nicola 2, Battria Richard 3, Galvin James 4, Henley David 5, De Santi Susan 6, Hampel Harald 7

1Eisai Inc - Hillsborough (United States); 2Rome University - Rome (Italy); 3Eisai Inc - Basel (Switzerland); 4Miami University - Miami (United States); 5Janssen - Indianapolis (United States); 6Eisai Inc - Nutley (United States)

**P177**

**Safety of fluorine 18-labeled amyloid tracers: pharmacovigilance validation using a large real-world database**

Kenichiro Sato 1, Yorichi Niimi 2, Ryoko Ibara 3, Kazushi Suzuki 4, Atsushi Iwata 3, Takeshi Iwatsubo 1

1University Of Tokyo - Tokyo (Japan); 2University Of Tokyo Hospital - Tokyo (Japan); 3Tokyo Metropolitan Geriatric Medical Center Hospital - Tokyo (Japan); 4National Defense Medical College - Saitama (Japan)

**P178**

**Diagnosis and clinical trial recruitment of patients with early onset Alzheimer’s disease in clinical practice: Single center experience in Japan**

Masanori Kurihara 1, Ryoko Ibara 2, Kenji Ishibashi 3, Kenji Ishii 3, Kazutomi Kanemaru 1, Atsushi Iwata 1

1Department Of Neurology, Tokyo Metropolitan Geriatric Hospital And Institute Of Gerontology - Tokyo (Japan); 2Research Team For Neuroimaging, Tokyo Metropolitan Geriatric Hospital And Institute Of Gerontology - Tokyo (Japan)

**P179**

**Treatment status of Alzheimer’s dementia using common data model in South Korea**

Song Jeong Yun 1, Jang Jae-Won 2

1Kangwon National University Hospital - Chuncheon (Korea, Republic of); 2Kangwon National University College of Medicine - Chuncheon (Korea, Republic of)

**P180**

**Globalization of Alzheimer disease clinical trials: recommendations for trial implementation in low- and middle-income countries**

Jorge Llibre-Guerra 1

1Washington University School Of Medicine In St.louis - St. Louis (United States)

**P181**

**The Minority Report: An Update on Minority recruitment from a large site in Central Florida**

Sandra Torres 1, Sheila Baez-Torres 1, Stephanie Cassidy 1, Brandon Lenox 1, Sean Stanton 1, Jennifer West 1

1K2 elements, Orlando, Fl. (United States)

**P182**

**Generalizability of cognitive results from clinical trial participants to older adult population: addressing external validity**

Vahan Aslanian 1, Howard N. Hodis 2, 3, 4, Jan St. John 1, 3, Naoko Kono 1, 2, Victor Henderson 1, Wendy J Mack 1

1Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States); 2Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States); 3Department of Medicine, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States); 4Department of Epidemiology and Department of Neurology and Neurological Sciences, School of Medicine, Stanford University - Stanford, Ca (United States)

**P184**

**Prevalence Estimations for the Alzheimer’s Disease’s Continuum in the US Health and Retirement Study**

Amir Abbas Tahami Monfared 1, 2, Guanwu Zhang 1, Aastha Chandak 1, 2, Artak Khachatryan 1, 2, Laura De Benedetti 3, Noemi Hummel 4

1Eisai Inc - Nutley (United States); 2Bios, McGill University – Montreal (Canada); 3Certara Inc. - New York (United States); 4Certara Ltd - Sheffield (United Kingdom); 5Certara Canada Corporation - Montreal (United States); 6Certara GmbH - Lörrach (Germany)

**P185**

**Association between A/T/N profiles and mortality in patients with cognitive disorders**

Méline Régy 1, 2, Aline Dugravot 1, Bernard Hanseuw 1, Julien Dumurgier 1

1CRESS U1153 Epidemiology of Ageing and neurodegenerative diseases (Inserm) - Paris (France); 2Brain Aging Lab (Catholic University of Louvain - Brussels (Belgium); 3Brain Aging Lab (St Luc Hospital) - Bruxelles (Belgium)

**P186**

**Ultra high risk and high predictability of Alzheimer’s disease onset in people with Down syndrome: implications for clinical trials**

Juan Fortea 1, 2, Alberto Lleo 1, 2, Alexandre Bejanin 1, 2, Maria Florencia Iulita 1, 2

1Memory Unit and Biomedical Research Institute Sant Pau (IBB Sant Pau), Neurology Department, Hospital de la Santa Creu i Sant Pau - Barcelona (Spain); 2Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERENED) - Madrid (Spain); 3Barcelona Down Medical Center, Fundación Catalana Síndrome de Down - Barcelona (Spain)
Asymptomatic extracranial carotid atherosclerosis and its association with incident Alzheimer's dementia  
Francesca Vitali 1, Ikeoluwapo Bolakale-Rufai 1, Gregory Branigan 1, Juan Arias 1, Eric Reiman 1, Roberta Brinton 1, Craig Weinkauf 1  
1University of Arizona - Tucson (United States)
P195  Astrocytic Regulatory mechanism on PM2.5-induced neuronal cell death and neuroinflammation
Seol-Heui Han 1, Ryeong-Eun Kim 2, Kyung Ja Kwon 2
1Department Of Neurology, Konkuk Hospital Medical Center, 120-1 Neungdong-Ro, Gwangjin-Gu - Seoul (Korea, Republic of), 2Department Of Neuroscience, School Of Medicine, Konkuk University - Seoul (Korea, Republic of)

P196  Impact of Semaglutide in Amyloid Positivity (ISAP): Protocol for a Randomised Double-Blind Placebo-Controlled Trial in Amyloid Positive Individuals
Ivan Koychev 1, Amanda Adler 1, Paul Edson 2, Brian Tom 3, Joanne Milton 4, Joe Butchart 4, Adam Hampshire 5, Charles Marshall 6, Elizabeth Coulthard 6, Henrik Zetterberg 7, Francesca Cormack 8, Catherine Mummery 9, Rury Holman 10
1University of Oxford - Oxford (United Kingdom), 2Imperial College London - London (United Kingdom), 3University of Cambridge - Cambridge (United Kingdom), 4Royal Devon University Healthcare NHS Foundation Trust - Exeter (United Kingdom), 5Queen Mary University of London - London (United Kingdom), 6University of Bristol - Bristol (United Kingdom), 7University of Gothenburg - Gothenburg (United Kingdom), 8Cambridge Cognition - Cambridge (United Kingdom), 9University College London - London (United Kingdom)

P197  The novel FKBP51-Hsp90 interaction inhibitor attenuates high-fat-induced cognitive impairment
Bengt Winblad 1, Lisha Wang 1, Jakub Wojciesak 1, Rajnish Kumar 1, Pavel Pavlov 1
1Karolinska Institutet - Stockholm (Sweden)

P198  Intracellular Aβ accumulation in hippocampal neurons leads to endosomal/lysosomal leakage
Sophia Schedin Weiss 1, Yang Gao 1, Lars Tjernberg 1
1Karolinska Institutet - Solna (Sweden)

P199  ALZ-201, a monoclonal antibody therapy for specific neutralisation of toxic amyloid-β in Alzheimer’s disease
Anders Sandberg 1
1Alzinova AB - Gothenburg (Sweden)

P200  Reducing toxic amyloid-β oligomers in AD through precise targeting of the molecular mechanisms of oligomer formation with small molecule inhibitors
Johnny Habchi 1, Kerry Jenkins 1, Samata Pandey 1, Roxine Staats 1, Sunehera Sarwat 1, Benedetta Mannini 1, Xiaoting Yang 1, Luke Rajah 1, Samuel Cohen 1, Suzanne Brewerton 1, Allyen Plowright 1
1Wren Therapeutics Limited - Cambridge (United Kingdom)

P201  The bromodomain and extraterminal domain protein inhibitor apabetalone inhibits the neurotoxic kynurenine pathway in monocytes and brain endothelial cells
Sylwia Wasiak 1, Li Fu 1, Stephanie Stotz 1, Dean Gilham 1, Laura Tsujikawa 1, Stefania Zerial 3, Annika Wagener 4, Yurieksy Andrade-Talavera 1, Frederico Picciau 2, Caterina Grassi 3, Gefe Chen 4, André Fischer 1, Bernd Schröder 7, Per Nilsson 1
1Resverlogix - Calgary (Canada), 2University of Amsterdam - Amsterdam (Netherlands), 3Resverlogix - San Francisco (United States)

P202  A novel therapeutic approach to treat Alzheimer’s disease: The brain-specific signal peptide peptidase-like 2b (SPPL2b)
Simone Tambaro 1, Riccardo Maccioni 2, Caterina Travisan 3, Stefania Zerial 3, Annika Wagener 4, Yurieksy Andrade-Talavera 1, Federico Picciau 2, Caterina Grassi 3, Gefe Chen 4, André Fischer 1, Bernd Schröder 7, Per Nilsson 1
1Department of Biomedical Sciences, Neuroscience and Clinical Pharmacology, University of Cagliari - Cagliari (Italy), 2Department of Neurobiology, Care Sciences and Society (NVS) Division of Neurogeriatrics, Karolinska Institutet - Solna (Sweden), 3Department of Neurobiology, Care Sciences and Society (NVS) Division of Neuroscience, Karolinska Institutet - Solna (Sweden), 4Department of Biomedical Sciences, Neuroscience and Clinical Pharmacology, University of Cagliari - Cagliari (Italy), 5Department of Life science, University of Trieste - Trieste (Italy), 6Interdisciplinary center for Neuroscience, Heidelberg University - Heidelberg (Germany), 7Department of Pharmacy and Biotechnology, University of Bologna - Bologna (Italy), 8Department of Biosciences and Nutrition, Karolinska Institutet - Huddinge (Sweden), 9Institute of Physiological Chemistry, Technische Universität Dresden - Dresden (Germany)

P203  Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis
Richeng Jiang 1, Una Smailovic 1, Hazal Haytural 1, Betty Tijms 2, Hao Li 3, Aage Skovhus 4, Johan Gobom 1, Sofie Nyström 3, Per Hammarström 3, Sina Syvänen 1, Henrik Zetterberg 1, Bengt Winblad 1, Jonas Bergquist 2, Pieter Jelle Visser 2, Per Nilsson 1
1Karolinska Institutet - Stockholm (Sweden), 2Amsterdam UMC - Amsterdam (Netherlands), 3Uppsala University - Uppsala (Sweden), 4Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden), 5Linköping University - Linköping (Sweden)

P204  Antibodies generated against an Aβ-derived oligomer: Efforts toward a novel Alzheimer’s disease immunotherapy
Chelsea Marie Parrocha 1, Adam Kreutzer 2, Jesse Pascual 3, Cherie Stringer 3, Jennifer Nguyen 1, Ashley Ith 1, Elizabeth Head 3, James Novick 2,1
1Department of Pharmaceutical Sciences, University of California Irvine - Irvine (United States), 2Department of Chemistry, University of California Irvine - Irvine (United States), 3Department of Pathology and Laboratory Medicine, University of California Irvine - Irvine (United States)
Efficacy of the ‘Finger-to-brain’ game on cognitive function of older adults with mild cognitive impairment: a randomized controlled crossover trial
Ji Won Han 1,2, Dong Gyu Moon 1, Jung UK Shin 1, Yeseung Park 1, Min Jeong Kwon 3, Hae In Kim 1, Woori Moon 1, Dae Jong Oh 1,2, Jong Bin Bae 1,2, Ki Woong Kim 1,2,3
1Department Of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam-Si (Korea, Republic of), 2Department of Psychiatry, Seoul National University College of Medicine - Seoul (Korea, Republic of), 3Department Of Brain And Cognitive Science, Seoul National University College Of Natural Sciences - Seoul (Korea, Republic of), 4Department Of Psychiatry, Snu Boramae Medical Center - Seoul (Korea, Republic of), 5Department Of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam-si (Korea, Republic of)

Feasibility, acceptability, and adherence of a remote smartphone-based self-assessment of cognition, function, and behavior in early Alzheimer’s disease
Thanheen Malai Perumal 1, Arnaud Wolfer 1, Miguel Veloso 2, Irma T. Kurniawan 1, Golou Keita 3, Niels Hagenbuch 4, Beijue Shi 5, Foteini Orfaniotou 5, David Watson 5, Mercè Boada Rovira 6, Kirsten I. Taylor 7
1Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), 2Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 3F. Hoffmann-La Roche Ltd., 4Cytel Inc., 5Geneve (Switzerland), 6Global Product Development Data And Statistical Sciences, 7F. Hoffmann-La Roche Ltd. - Basel (Switzerland)

A Multimodal Deep Learning Approach to Prediction of Cognitive Decline and its Potential Application in Clinical Trials for Alzheimer’s Disease
Caihua Wang 1, Yuanzhong Li 1, Hiroyuki Yamashita 2
1Imaging Technology Center, FUJIFILM Corporation - Kanagawa (Japan), 2Department of Information Medicine, National Institute of Neuroscience, National Institute of Neurology and Psychiatry - Tokyo (Japan), 3Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry - Tokyo (Japan), 4Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry - Tokyo (Japan)

Increasing Study Power via Frequent Speech-Based Assessments of Cognition
Gabriela Stegmann 1, Shira Hahn 1, Julie Liss 1, Visar Berisha 1, Kimberly Mueller 2
1Arizona State University and Aural Analytics - Scottsdale, Az (United States), 2University of Wisconsin - Madison - Madison, Wi (United States)

Preliminary Results of a Digital Pilot to Improve AD Trial Retention by Managing Caregiver Stress
Rosemary Laird 1,2, Jessica Branning 1
1ClinCloud Clinical Trials - Viera (United States), 2Navigating Aging Needs LLC - Orlando (United States)

Brain Network Difference between Mild Cognitive Impairment and Alzheimer’s Disease Dementia Using EEG
Hong Yuseong 1, Baik Kyoungwon 2, Park Ukeob 3, Ye Byoung Seok 2, Kang Seung Won 1
1MedSync Inc. - Seoul (Korea, Republic of), 2Yonsei University College of Medicine - Seoul (Korea, Republic of)

Using Ecological Momentary Assessment to Measure Real-World Effects of a Combined Computerized Cognitive and Functional Skills training Program in Mild Cognitive Impairment
Philip Harvey 1, Peter Kallestrup 3, Sara Czaja 2
1University of Miami Miller School of Medicine - Miami (United States), 2Function - Miami (United States), 3Weill Cornell Medical Center - New York (United States)

The effects of home-based cognitive intervention with chat-bot on brain function in patients with amnestic mild cognitive impairment
Geon Ha Kim 1, Bori Kim 1, Jee Hyang Jeong 1
1EwhaW University - Seoul (Korea, Republic of)

Remote computer-based cognitive training: short- and long-term benefits on cognition and daily living in patients with Alzheimer’s disease
Samar Dimachki 1, Franck Tarpin-Bernard 1, Stéphane De Chalvron 1, Bernard Crosbie 1, Hanna Chainay 1
1Laboratoire d’Étude des Mécanismes Cognitifs, Université Lyon 2 - Lyon (France), 2Scientific Brain Training SA - Lyon (France), 3Service de Neuropsychologie, Centre Mémoire de Ressource et de Recherche de Lyon, Hôpital Neurologique - Lyon (France)

Taking care of family dementia caregivers: a qualitative examination of patient perspectives and perceived health outcomes after receiving usual care and after a digitally supported care management program
Olga Klein 1, Antonia Karras 2, Wolfgang Hoffmann 3,4, Stefan Teipel 1,2, Ingo Kilimann 1,2
1Deutsches Zentrum fuer Neurodegenerative Erkrankungen - Rostock (Germany), 2Rostock (Germany), 3Clinic for Psychosomatics and Psychotherapy, University Medical Center Rostock - Rostock (Germany), 4Deutsches Zentrum fuer Neurodegenerative Erkrankungen - Greifswald (Germany), 5Institute for Community Medicine, Section Epidemiology and Community Health, University Medical Center Greifswald - Greifswald (Germany)

Intuition: a brain health study using multimodal digital biomarkers to decipher cognitive profiles of individuals at-risk for Alzheimer’s and related dementias
Monroe Butler 1, Anton Porsteinsson 2, Sean Kenny 1, Hansen Lenyou 1, Matt Hobbs 1, Roland Brown 1, Matt Bianchi 3, James Williams 1, Audrey Gabelle 1, Shibeshish Belachew 1
1Intuition Study Scientific Committee Intuition Study Scientific Committee, 2University of Rochester Medical Center - Rochester (United States), 3Apple - Cupertino (United States)
It is reminded that the papers presented during the Congress, whatever their form (oral, written or poster) are placed under the sole responsibility of their authors and co-authors. In no case, the positions, research, results presented during the CTAD Congress & published in the JPAD are likely to engage the responsibility of the Congress.
Practical Details

Conference Venue
HILTON UNION SQUARE
333 O’Farrell Street
San Francisco, CA 94102

MEETING ROOMS
> Conference Room
All sessions will be held in Grand Ballroom AB - Tower 2.

> Posters Sessions and Coffee Breaks
Yosemite/Imperial Ballrooms – Tower 2
Meet our poster presenters during the coffee breaks. A poster assistance desk will be available to locate the posters – Days of poster presentations are on page 24.

NEW at CTAD this year
Enjoy a morning coffee while touring the posters from 8 a.m to 9 a.m on Wednesday, Thursday and Friday.

Free WiFi available at CTAD
Network: CTAD22 - Password: CTAD22

> Mobile App
Download the VFairs mobile app on the Apple Store or Google Play. Login with the email address used to register, then click on CTAD22 and enjoy the conference at your fingertips, you can watch the livestream from the Ballroom, access the virtual poster hall and connect with your colleagues!

> CTAD22 digital platform
To access our digital platform simply go to www.ctad22.com and enter with your email address.

> Speaker ready room opening hours:
- Tuesday, November 29: 1 p.m to 6 p.m
- Wednesday, November 30 to Friday, December 2: 7:30 a.m to 5:30 p.m

> Lunch on your own at CTAD22
A complete list of restaurants and take-out outlets is available in your attendee bag and on the CTAD22 Mobile App. Coffee will be available from 1:00 to 1:30 p.m to enjoy the poster presentations.

> CTAD Welcome Reception
Tuesday, November 29 from 6:30 p.m to 7:30 p.m
Continental Ballroom – Tower 3
CTAD would like to thank its 2022 privileged partners for their continued support.

Platinum Sponsor

Alzheimer's Drug Discovery Foundation

Gold Sponsors

Alzheimer's Association

Biogen

Eisai

Lilly

Lundbeck

Novo Nordisk

Otsuka

Roche
Follow us on social media!

@CTADConference #CTAD22
CTAD Conference
CTAD Alzheimer

Email: ctad@ant-congres.com
www.ctad-alzheimer.com